

The Bronchiectasis Severity Index. An International De

American Journal of Respiratory and Critical Care Medicine
189, 576-585

DOI: [10.1164/rccm.201309-1575oc](https://doi.org/10.1164/rccm.201309-1575oc)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Non-cystic fibrosis bronchiectasis: an evidence-base for new therapies. <i>Lancet Respiratory Medicine</i> ,the, 2014, 2, 958-960.	5.2	7
2	The effect of long-term macrolide treatment on respiratory microbiota composition in non-cystic fibrosis bronchiectasis: an analysis from the randomised, double-blind, placebo-controlled BLESS trial. <i>Lancet Respiratory Medicine</i> ,the, 2014, 2, 988-996.	5.2	146
3	Is COPD in its age of enlightenment?. <i>Lancet Respiratory Medicine</i> ,the, 2014, 2, 960-962.	5.2	0
5	Bronchiectasis Severity: Time to Score. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2014, 189, 508-509.	2.5	5
6	COPD and Bronchiectasis: Phenotype, Endotype or Co-morbidity?. <i>COPD: Journal of Chronic Obstructive Pulmonary Disease</i> , 2014, 11, 603-604.	0.7	40
7	Aztreonam for inhalation solution in patients with non-cystic fibrosis bronchiectasis (AIR-BX1 and) Tj ETQq1 1 0.784314 rgBT /Overlook <i>Medicine</i> ,the, 2014, 2, 738-749.	5.2	172
8	Bronchiectasis trials: losing the battle but winning the war?. <i>Lancet Respiratory Medicine</i> ,the, 2014, 2, 679-681.	5.2	4
9	Nebulized Colistin for Non-“Cystic Fibrosis Bronchiectasis: DÃ©jÃ Vu All Over Again?. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2014, 189, 1151-1152.	2.5	9
10	Antimicrobial treatment of non-cystic fibrosis bronchiectasis. <i>Expert Review of Anti-Infective Therapy</i> , 2014, 12, 1277-1296.	2.0	27
11	Molecular epidemiological analysis suggests cross-infection with <i>Pseudomonas aeruginosa</i> is rare in non-cystic fibrosis bronchiectasis. <i>European Respiratory Journal</i> , 2014, 43, 900-903.	3.1	25
12	How to assess the severity of bronchiectasis. <i>European Respiratory Journal</i> , 2014, 43, 1217-1219.	3.1	14
13	Macrolides for bronchiectasis and chronic obstructive pulmonary disease: should we worry about antimicrobial resistance?. <i>Clinical Investigation</i> , 2014, 4, 591-594.	0.0	2
14	Interventions for bronchiectasis: an overview of Cochrane systematic reviews. <i>The Cochrane Library</i> , 2015, 2015, CD010337.	1.5	56
15	Hiatal hernias are correlated with increased severity of non-“cystic fibrosis bronchiectasis. <i>Respirology</i> , 2015, 20, 749-757.	1.3	37
16	Sputum matrix metalloproteinase-8 and -9 and tissue inhibitor of metalloproteinase-1 in bronchiectasis: Clinical correlates and prognostic implications. <i>Respirology</i> , 2015, 20, 1073-1081.	1.3	31
18	Prolonged antibiotics for non-cystic fibrosis bronchiectasis in children and adults. <i>The Cochrane Library</i> , 2017, 2017, CD001392.	1.5	39
19	Distribution of Major Pathogens from Sputum and Bronchoalveolar Lavage Fluid in Patients with Noncystic Fibrosis Bronchiectasis. <i>Chinese Medical Journal</i> , 2015, 128, 2792-2797.	0.9	17
20	P202-“Assessment of bronchiectasis scoring systems: a long term cohort study. <i>Thorax</i> , 2015, 70, A178.2-A179.	2.7	0

#	ARTICLE	IF	CITATIONS
21	Neutrophilic Bronchial Inflammation Correlates with Clinical and Functional Findings in Patients with Noncystic Fibrosis Bronchiectasis. <i>Mediators of Inflammation</i> , 2015, 2015, 1-6.	1.4	50
22	The Role of Viral Infection in Pulmonary Exacerbations of Bronchiectasis in Adults. <i>Chest</i> , 2015, 147, 1635-1643.	0.4	109
24	Reclaiming the name "bronchiectasis". <i>Thorax</i> , 2015, 70, 399-400.	2.7	28
25	Imaging in Cystic Fibrosis and Non-Cystic Fibrosis Bronchiectasis. <i>Seminars in Respiratory and Critical Care Medicine</i> , 2015, 36, 194-206.	0.8	28
26	Aetiology and clinical characteristics of patients with bronchiectasis in a Chinese Han population: A prospective study. <i>Respirology</i> , 2015, 20, 917-924.	1.3	53
27	Secreted mucins and airway bacterial colonization in non-CF bronchiectasis. <i>Respirology</i> , 2015, 20, 1082-1088.	1.3	43
28	Lung allocation score and health-related quality of life in Japanese candidates for lung transplantation. <i>Interactive Cardiovascular and Thoracic Surgery</i> , 2015, 21, 28-33.	0.5	15
29	Bronchiectasis: working together for better evidence. <i>Lancet Respiratory Medicine</i> , 2015, 3, 915-917.	5.2	0
30	Sputum bacteriology in steady-state bronchiectasis in Guangzhou, China. <i>International Journal of Tuberculosis and Lung Disease</i> , 2015, 19, 610-619.	0.6	35
31	Inhaled antibiotics for bronchiectasis: are we there yet?. <i>Current Pulmonology Reports</i> , 2015, 4, 198-204.	0.5	1
32	Use of Inhaled Tobramycin in Cystic Fibrosis. <i>Advances in Therapy</i> , 2015, 32, 1-9.	1.3	21
33	Genetics, diagnosis and future treatment strategies for primary ciliary dyskinesia. <i>Expert Opinion on Orphan Drugs</i> , 2015, 3, 31-44.	0.5	14
34	Emerging drugs for bronchiectasis: an update. <i>Expert Opinion on Emerging Drugs</i> , 2015, 20, 277-297.	1.0	8
35	Lung function, symptoms and inflammation during exacerbations of non-cystic fibrosis bronchiectasis: a prospective observational cohort study. <i>Respiratory Research</i> , 2015, 16, 16.	1.4	60
36	Impulse Oscillometry in Adults with Bronchiectasis. <i>Annals of the American Thoracic Society</i> , 2015, 12, 657-665.	1.5	33
38	Six-minute walk test in Chinese adults with clinically stable bronchiectasis: association with clinical indices and determinants. <i>Current Medical Research and Opinion</i> , 2015, 31, 843-852.	0.9	12
39	Efficacy and Safety of Nintedanib in Idiopathic Pulmonary Fibrosis, Cytisine versus Nicotine for Smoking Cessation, and FACED Score for Non-Cystic Fibrosis Bronchiectasis. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2015, 192, 249-251.	2.5	2
40	COPD-bronchiectasis overlap syndrome. <i>European Respiratory Journal</i> , 2015, 45, 310-313.	3.1	139

#	ARTICLE	IF	CITATIONS
41	Aetiology of bronchiectasis in Guangzhou, southern China. <i>Respirology</i> , 2015, 20, 739-748.	1.3	70
42	Management of bronchiectasis in adults. <i>European Respiratory Journal</i> , 2015, 45, 1446-1462.	3.1	220
43	Challenges in the development of new therapies for bronchiectasis. <i>Expert Opinion on Pharmacotherapy</i> , 2015, 16, 833-850.	0.9	20
44	Bronchiectasis. <i>Current Opinion in Pulmonary Medicine</i> , 2015, 21, 272-277.	1.2	4
45	Bronchiectasis in Germany: a population-based estimation of disease prevalence. <i>European Respiratory Journal</i> , 2015, 46, 1805-1807.	3.1	122
46	Diagnostic approach to bronchiectasis. <i>Current Pulmonology Reports</i> , 2015, 4, 191-197.	0.5	1
47	Etiology of Non-Cystic Fibrosis Bronchiectasis in Adults and Its Correlation to Disease Severity. <i>Annals of the American Thoracic Society</i> , 2015, 12, 1764-1770.	1.5	233
48	Sedentary behaviour and physical activity in bronchiectasis: a cross-sectional study. <i>BMC Pulmonary Medicine</i> , 2015, 15, 61.	0.8	42
50	A Comprehensive Analysis of the Impact of <i>Pseudomonas aeruginosa</i> Colonisation on Prognosis in Adult Bronchiectasis. <i>Annals of the American Thoracic Society</i> , 2015, 12, 1602-11.	1.5	258
51	Bronchiectasis in adults: epidemiology, assessment of severity and prognosis. <i>Current Pulmonology Reports</i> , 2015, 4, 142-151.	0.5	1
52	Update in Bronchiectasis 2014. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2015, 192, 1155-1161.	2.5	19
53	Non cystic fibrosis bronchiectasis: A longitudinal retrospective observational cohort study of <i>Pseudomonas</i> persistence and resistance. <i>Respiratory Medicine</i> , 2015, 109, 716-726.	1.3	107
54	Non-antibiotic Inhaled Agents for Stable Non-CF Bronchiectasis in Adults - A Systematic Review. <i>Journal of Pulmonary & Respiratory Medicine</i> , 2016, 06, .	0.1	0
55	Bronquiectasias: ¿No es más una enfermedad huérfana?. <i>Revista Chilena De Enfermedades Respiratorias</i> , 2016, 32, 169-177.	0.1	0
56	The factors affecting survival in patients with bronchiectasis. <i>Turkish Journal of Medical Sciences</i> , 2016, 46, 1838-1845.	0.4	4
57	Video-assisted thoracoscopic superior segmentectomy of the right lower lobe. <i>Journal of Thoracic Disease</i> , 2016, 8, 1349-1352.	0.6	2
58	A global perspective of lung transplantation: Part 1 - Recipient selection and choice of procedure. <i>Global Cardiology Science & Practice</i> , 2016, 2016, e201605.	0.3	5
59	Characterizing Non-Tuberculous Mycobacteria Infection in Bronchiectasis. <i>International Journal of Molecular Sciences</i> , 2016, 17, 1913.	1.8	70

#	ARTICLE	IF	CITATIONS
60	Bronchiectasis in the Last Five Years: New Developments. <i>Journal of Clinical Medicine</i> , 2016, 5, 115.	1.0	16
61	Quality standards for the management of bronchiectasis in Italy: a national audit. <i>European Respiratory Journal</i> , 2016, 48, 244-248.	3.1	33
62	Ciprofloxacin dry powder for inhalation in non-cystic fibrosis bronchiectasis. <i>Expert Opinion on Orphan Drugs</i> , 2016, 4, 875-884.	0.5	9
63	Factors associated with radiologic progression of non-cystic fibrosis bronchiectasis during long-term follow-up. <i>Respirology</i> , 2016, 21, 1049-1054.	1.3	31
64	Multidimensional severity assessment in bronchiectasis: an analysis of seven European cohorts. <i>Thorax</i> , 2016, 71, 1110-1118.	2.7	128
66	Inhaled Antibiotics for Gram-Negative Respiratory Infections. <i>Clinical Microbiology Reviews</i> , 2016, 29, 581-632.	5.7	97
67	Lung transplantation for non-cystic fibrosis bronchiectasis. <i>Respiratory Medicine</i> , 2016, 115, 60-65.	1.3	26
68	Non CF-bronchiectasis: Aetiologic approach, clinical, radiological, microbiological and functional profile in 277 patients. <i>Respiratory Medicine</i> , 2016, 116, 1-7.	1.3	64
69	Bronchiectasis: Current Concepts in Pathogenesis, Immunology, and Microbiology. <i>Annual Review of Pathology: Mechanisms of Disease</i> , 2016, 11, 523-554.	9.6	84
70	Phenotyping bronchiectasis: is it all about sputum and infection?. <i>European Respiratory Journal</i> , 2016, 47, 1037-1039.	3.1	7
71	Aerosolized Antibiotics for Patients with Bronchiectasis. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2016, 193, 808-810.	2.5	15
72	Unsupervised learning technique identifies bronchiectasis phenotypes with distinct clinical characteristics. <i>International Journal of Tuberculosis and Lung Disease</i> , 2016, 20, 402-410.	0.6	38
73	Mortality among patients with pulmonary non-tuberculous mycobacteria disease. <i>International Journal of Tuberculosis and Lung Disease</i> , 2016, 20, 582-587.	0.6	73
74	Risk factors for requiring intravenous antibiotic therapy in hospital and 30-day readmission for exacerbations of bronchiectasis. <i>QJM - Monthly Journal of the Association of Physicians</i> , 2016, 109, 723-729.	0.2	3
75	Global impact of bronchiectasis and cystic fibrosis. <i>Breathe</i> , 2016, 12, 222-235.	0.6	51
76	The best of respiratory infections from the 2015 European Respiratory Society International Congress. <i>ERJ Open Research</i> , 2016, 2, 00049-2016.	1.1	0
77	Macrolides for Clinically Significant Bronchiectasis in Adults. <i>Chest</i> , 2016, 150, 1187-1193.	0.4	25
78	Characterization of bronchiectasis in the elderly. <i>Respiratory Medicine</i> , 2016, 119, 13-19.	1.3	28

#	ARTICLE	IF	CITATIONS
79	Impulse Oscillometry and Spirometry Small-Airway Parameters in Mild to Moderate Bronchiectasis. <i>Respiratory Care</i> , 2016, 61, 1513-1522.	0.8	14
80	Phenotyping Adults with Non-Cystic Fibrosis Bronchiectasis: A 10-Year Cohort Study in a French Regional University Hospital Center. <i>Respiration</i> , 2016, 92, 1-8.	1.2	33
81	Is it feasible to radiologically monitor the evolution of non-CF bronchiectasis?. <i>Respirology</i> , 2016, 21, 1137-1137.	1.3	2
82	Comorbidities and the risk of mortality in patients with bronchiectasis: an international multicentre cohort study. <i>Lancet Respiratory Medicine</i> , 2016, 4, 969-979.	5.2	210
83	Long-term antibiotic treatment for non-cystic fibrosis bronchiectasis in adults: evidence, current practice and future use. <i>Expert Review of Respiratory Medicine</i> , 2016, 10, 1259-1268.	1.0	6
84	Macrolide antibiotics for non-cystic fibrosis bronchiectasis. <i>The Cochrane Library</i> , 2016, , .	1.5	5
85	Primary ciliary dyskinesia. <i>Current Pulmonology Reports</i> , 2016, 5, 191-198.	0.5	0
87	A longitudinal study characterising a large adult primary ciliary dyskinesia population. <i>European Respiratory Journal</i> , 2016, 48, 441-450.	3.1	101
88	Research priorities in bronchiectasis: a consensus statement from the EMBARC Clinical Research Collaboration. <i>European Respiratory Journal</i> , 2016, 48, 632-647.	3.1	170
89	Challenges in managing <i>Pseudomonas aeruginosa</i> in non-cystic fibrosis bronchiectasis. <i>Respiratory Medicine</i> , 2016, 117, 179-189.	1.3	70
90	Efficacy and safety of long-term inhaled antibiotic for patients with noncystic fibrosis bronchiectasis: a meta-analysis. <i>Clinical Respiratory Journal</i> , 2016, 10, 731-739.	0.6	44
92	Applying the Transtheoretical Model to Physical Activity Behavior in Individuals With Non-Cystic Fibrosis Bronchiectasis. <i>Respiratory Care</i> , 2016, 61, 68-77.	0.8	9
93	The validity of health-related quality of life questionnaires in bronchiectasis: a systematic review and meta-analysis. <i>Thorax</i> , 2016, 71, 683-694.	2.7	50
94	Bronchiectasis in China. <i>Annals of the American Thoracic Society</i> , 2016, 13, 609-616.	1.5	57
95	The generalizability of bronchiectasis randomized controlled trials: A multicentre cohort study. <i>Respiratory Medicine</i> , 2016, 112, 51-58.	1.3	27
96	The bronchiectasis severity index and FACED score for bronchiectasis. <i>European Respiratory Journal</i> , 2016, 47, 382-384.	3.1	25
97	Clinical phenotypes in adult patients with bronchiectasis. <i>European Respiratory Journal</i> , 2016, 47, 1113-1122.	3.1	215
98	Validation of a Spanish version of the Leicester Cough Questionnaire in non-cystic fibrosis bronchiectasis. <i>Chronic Respiratory Disease</i> , 2016, 13, 128-136.	1.0	32

#	ARTICLE	IF	CITATIONS
99	The EMBARC European Bronchiectasis Registry: protocol for an international observational study. ERJ Open Research, 2016, 2, 00081-2015.	1.1	133
100	Bronchiectasis: how to be an orphan with many parents?. European Respiratory Journal, 2016, 47, 10-13.	3.1	44
101	Predicting mortality in bronchiectasis using bronchiectasis severity index and FACED scores: a 19-year cohort study. European Respiratory Journal, 2016, 47, 482-489.	3.1	66
102	Inhaled antibiotics in the treatment of non-cystic fibrosis bronchiectasis: clinical and drug delivery perspectives. Expert Opinion on Drug Delivery, 2016, 13, 7-22.	2.4	18
103	Dual antibiotics for non-cystic fibrosis bronchiectasis. The Cochrane Library, 2017, , .	1.5	6
104	Disbiosis microbiana en las bronquiectasias y la fibrosis quística. Archivos De Bronconeumología, 2017, 53, 471-472.	0.4	1
105	Eosinophilia associated with Strongyloides infection, severe asthma, and central bronchiectasis. Annals of Allergy, Asthma and Immunology, 2017, 118, 510-511.	0.5	0
106	Self-management for non-cystic fibrosis bronchiectasis. The Cochrane Library, 0, , .	1.5	2
107	Etiología de las bronquiectasias en una cohorte de 2.047 pacientes. Análisis del registro histórico español. Archivos De Bronconeumología, 2017, 53, 366-374.	0.4	67
108	Understanding COPD-overlap syndromes. Expert Review of Respiratory Medicine, 2017, 11, 285-298.	1.0	47
109	Comparing accelerometer, pedometer and a questionnaire for measuring physical activity in bronchiectasis: a validity and feasibility study. Respiratory Research, 2017, 18, 16.	1.4	48
110	Suspecting non-cystic fibrosis bronchiectasis: What the busy primary care clinician needs to know. International Journal of Clinical Practice, 2017, 71, e12924.	0.8	19
111	Bronchiectasis Rheumatoid Overlap Syndrome Is an Independent Risk Factor for Mortality in Patients With Bronchiectasis. Chest, 2017, 151, 1247-1254.	0.4	81
112	Short-Term Effect of Autogenic Drainage on Ventilation Inhomogeneity in Adult Subjects With Stable Non-Cystic Fibrosis Bronchiectasis. Respiratory Care, 2017, 62, 524-531.	0.8	14
113	Sex bias in diagnostic delay in bronchiectasis: An analysis of the Spanish Historical Registry of Bronchiectasis. Chronic Respiratory Disease, 2017, 14, 360-369.	1.0	18
114	The development and validation of the Bronchiectasis Health Questionnaire. European Respiratory Journal, 2017, 49, 1601532.	3.1	63
115	The RESPIRE trials: Two phase III, randomized, multicentre, placebo-controlled trials of Ciprofloxacin Dry Powder for Inhalation (Ciprofloxacin DPI) in non-cystic fibrosis bronchiectasis. Contemporary Clinical Trials, 2017, 58, 78-85.	0.8	39
116	Sputum Neutrophil Elastase as a Biomarker for Disease Activity in Bronchiectasis. American Journal of Respiratory and Critical Care Medicine, 2017, 195, 1289-1291.	2.5	8

#	ARTICLE	IF	CITATIONS
117	Anti-Pseudomonas aeruginosa IgG antibodies and chronic airway infection in bronchiectasis. <i>Respiratory Medicine</i> , 2017, 128, 1-6.	1.3	18
118	Pharmacotherapy for Non-Cystic Fibrosis Bronchiectasis. <i>Chest</i> , 2017, 152, 1120-1127.	0.4	36
119	The heterogeneity of systemic inflammation in bronchiectasis. <i>Respiratory Medicine</i> , 2017, 127, 33-39.	1.3	58
120	The Role of Neutrophil Elastase Inhibitors in Lung Diseases. <i>Chest</i> , 2017, 152, 249-262.	0.4	158
121	Patterns of Disease in Patients with Middle-Lobe Predominant Bronchiectasis. <i>Respiration</i> , 2017, 93, 406-414.	1.2	10
122	Non-Cystic Fibrosis Bronchiectasis: from Programmatic Management to Personalized Medicine. <i>Respiration</i> , 2017, 93, 404-405.	1.2	0
123	Quantitative CT Measures of Bronchiectasis in Smokers. <i>Chest</i> , 2017, 151, 1255-1262.	0.4	55
124	Neutrophil Elastase Activity Is Associated with Exacerbations and Lung Function Decline in Bronchiectasis. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2017, 195, 1384-1393.	2.5	232
125	Health-related quality of life questionnaires in bronchiectasis: the simplest way to quantify complexity. <i>European Respiratory Journal</i> , 2017, 49, 1700208.	3.1	4
126	Diagnosis and management of bronchiectasis. <i>Cmaj</i> , 2017, 189, E828-E835.	0.9	26
127	Serum Albumin and Disease Severity of Non-Cystic Fibrosis Bronchiectasis. <i>Respiratory Care</i> , 2017, 62, 1075-1084.	0.8	11
128	An update on pediatric bronchiectasis. <i>Expert Review of Respiratory Medicine</i> , 2017, 11, 517-532.	1.0	25
129	A Randomized Controlled Trial of Atorvastatin in Patients With Bronchiectasis Infected With Pseudomonas Aeruginosa. <i>Chest</i> , 2017, 152, 368-378.	0.4	31
130	The challenge of defining exacerbation in bronchiectasis. <i>European Respiratory Journal</i> , 2017, 49, 1700700.	3.1	2
131	Cough and bronchiectasis. <i>Pulmonary Pharmacology and Therapeutics</i> , 2017, 47, 77-83.	1.1	15
132	The Use of Plasmapheresis in Patients with Bronchiectasis with Pseudomonas aeruginosa Infection and Inhibitory Antibodies. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2017, 195, 955-958.	2.5	11
133	Microbial Dysbiosis in Bronchiectasis and Cystic Fibrosis. <i>Archivos De Bronconeumologia</i> , 2017, 53, 471-472.	0.4	1
134	New therapies for the prevention and treatment of exacerbations of bronchiectasis. <i>Current Opinion in Pulmonary Medicine</i> , 2017, 23, 218-224.	1.2	8

#	ARTICLE	IF	CITATIONS
135	Prolonged Apnea Supported by High-Frequency Noninvasive Ventilation: A Pilot Study. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2017, 195, 958-960.	2.5	14
136	Raising awareness of bronchiectasis in primary care: overview of diagnosis and management strategies in adults. <i>Npj Primary Care Respiratory Medicine</i> , 2017, 27, 18.	1.1	32
137	Bronchiectasis: Phenotyping a Complex Disease. <i>COPD: Journal of Chronic Obstructive Pulmonary Disease</i> , 2017, 14, S12-S18.	0.7	26
138	Factors associated with hospitalization in bronchiectasis exacerbations: a one-year follow-up study. <i>Respiratory Research</i> , 2017, 18, 176.	1.4	30
139	Patient participation in ERS guidelines and research projects: the EMBARC experience. <i>Breathe</i> , 2017, 13, 194-207.	0.6	20
140	Positive expiratory pressure therapy versus other airway clearance techniques for bronchiectasis. <i>The Cochrane Library</i> , 2017, 2017, CD011699.	1.5	47
141	European Respiratory Society guidelines for the management of adult bronchiectasis. <i>European Respiratory Journal</i> , 2017, 50, 1700629.	3.1	788
142	The European Multicentre Bronchiectasis Audit and Research Collaboration (EMBARC): experiences from a successful ERS Clinical Research Collaboration. <i>Breathe</i> , 2017, 13, 180-192.	0.6	34
143	Profile of the ProAxis active neutrophil elastase immunoassay for precision medicine in chronic respiratory disease. <i>Expert Review of Molecular Diagnostics</i> , 2017, 17, 875-884.	1.5	10
144	Screening protocols to monitor respiratory status in primary immunodeficiency disease: findings from a European survey and subclinical infection working group. <i>Clinical and Experimental Immunology</i> , 2017, 190, 226-234.	1.1	25
145	The respiratory threat posed by multidrug resistant <i>G</i> negative bacteria. <i>Respirology</i> , 2017, 22, 1288-1299.	1.3	84
146	The Objective Assessment of Cough Frequency in Bronchiectasis. <i>Lung</i> , 2017, 195, 575-585.	1.4	18
147	Continuous versus intermittent antibiotics for non-cystic fibrosis bronchiectasis. <i>The Cochrane Library</i> , 2017, .	1.5	2
148	Standardised classification of the aetiology of bronchiectasis using an objective algorithm. <i>European Respiratory Journal</i> , 2017, 50, 1701289.	3.1	63
149	Correlates and assessment of excess cardiovascular risk in bronchiectasis. <i>European Respiratory Journal</i> , 2017, 50, 1701127.	3.1	23
150	Etiology of Bronchiectasis in a Cohort of 2047 Patients. An Analysis of the Spanish Historical Bronchiectasis Registry. <i>Archivos De Bronconeumologia</i> , 2017, 53, 366-374.	0.4	36
151	Latin America validation of FACED score in patients with bronchiectasis: an analysis of six cohorts. <i>BMC Pulmonary Medicine</i> , 2017, 17, 73.	0.8	26
152	Bronchiectasis and <i>Aspergillus</i> : How are they linked?. <i>Medical Mycology</i> , 2017, 55, 69-81.	0.3	35

#	ARTICLE	IF	CITATIONS
153	Bronchoarterial ratio in never-smokers adults: Implications for bronchial dilation definition. <i>Respirology</i> , 2017, 22, 108-113.	1.3	28
154	Bronchitis, Bronchiectasis. , 2017, , 243-250.e2.		2
155	Bronchiectasis Severity Is an Independent Risk Factor for Vascular Disease in a Bronchiectasis Cohort. <i>Chest</i> , 2017, 151, 383-388.	0.4	24
156	Ciprofloxacin Dry Powder for Inhalation in Patients with Non-Cystic Fibrosis Bronchiectasis or Chronic Obstructive Pulmonary Disease, and in Healthy Volunteers. <i>Journal of Aerosol Medicine and Pulmonary Drug Delivery</i> , 2017, 30, 53-63.	0.7	21
157	Bronchiectasis—a growing respiratory problem. <i>NursePrescribing</i> , 2017, 15, 486-490.	0.1	0
158	Respiratory Diseases and Coronary Artery Diseases. <i>Indian Journal of Cardiovascular Disease in Women WINCARS</i> , 2017, 02, 056-067.	0.1	0
159	Predicting high risk of exacerbations in bronchiectasis: the E-FACED score. <i>International Journal of COPD</i> , 2017, Volume 12, 275-284.	0.9	138
160	Sensitization to <i>Aspergillus fumigatus</i> as a risk factor for bronchiectasis in COPD. <i>International Journal of COPD</i> , 2017, Volume 12, 2629-2638.	0.9	38
161	Inhaled Antibiotic Therapy in Chronic Respiratory Diseases. <i>International Journal of Molecular Sciences</i> , 2017, 18, 1062.	1.8	70
162	Healthcare Cost and Utilization before and after Diagnosis of <i>Pseudomonas aeruginosa</i> among Patients with Non-Cystic Fibrosis Bronchiectasis in the U.S.. <i>Medical Sciences (Basel, Switzerland)</i> , 2017, 5, 20.	1.3	9
163	Clinical impact of chronic obstructive pulmonary disease on non-cystic fibrosis bronchiectasis. A study on 1,790 patients from the Spanish Bronchiectasis Historical Registry. <i>PLoS ONE</i> , 2017, 12, e0177931.	1.1	22
164	Impact of chronic <i>Pseudomonas aeruginosa</i> infection on health-related quality of life in <i>Mycobacterium avium</i> complex lung disease. <i>BMC Pulmonary Medicine</i> , 2017, 17, 198.	0.8	23
165	Risk factors for multidrug-resistant pathogens in bronchiectasis exacerbations. <i>BMC Infectious Diseases</i> , 2017, 17, 659.	1.3	27
166	Is There a Correlation between New Scoring Systems and Systemic Inflammation in Stable Bronchiectasis?. <i>Canadian Respiratory Journal</i> , 2017, 2017, 1-6.	0.8	16
167	Bronchiectasis and increased risk of ischemic stroke: a nationwide population-based cohort study. <i>International Journal of COPD</i> , 2017, Volume 12, 1375-1383.	0.9	20
168	Distance-saturation product of the 6-minute walk test predicts mortality of patients with non-cystic fibrosis bronchiectasis. <i>Journal of Thoracic Disease</i> , 2017, 9, 3168-3176.	0.6	27
169	Bronchiectasis: new therapies and new perspectives. <i>Lancet Respiratory Medicine</i> , the, 2018, 6, 715-726.	5.2	147
170	The annual prognostic ability of FACED and E-FACED scores to predict mortality in patients with bronchiectasis. <i>ERJ Open Research</i> , 2018, 4, 00139-2017.	1.1	13

#	ARTICLE	IF	CITATIONS
171	Impact of underlying cause of bronchiectasis on clinical outcome: A comparative study on CF and Non-CF bronchiectasis in Egyptian children. The Gazette of the Egyptian Paediatric Association, 2018, 66, 49-53.	0.1	0
172	Prevention of exacerbations in patients with stable non-cystic fibrosis bronchiectasis: a systematic review and meta-analysis of pharmacological and non-pharmacological therapies. BMJ Evidence-Based Medicine, 2018, 23, 96-103.	1.7	10
173	Moving forward: Bronchiectasis and chronic suppurative lung disease in children and adults in the 21st century. Respiriology, 2018, 23, 1004-1005.	1.3	3
174	Ciprofloxacin Dry Powder for Inhalation (ciprofloxacin DPI): Technical design and features of an efficient drugâ€“device combination. Pulmonary Pharmacology and Therapeutics, 2018, 50, 72-79.	1.1	45
175	Identification of Pseudomonas aeruginosa and airway bacterial colonization by an electronic nose in bronchiectasis. Respiratory Medicine, 2018, 136, 111-117.	1.3	21
176	Effects of exercise on secretion transport, inflammation, and quality of life in patients with noncystic fibrosis bronchiectasis. Medicine (United States), 2018, 97, e9768.	0.4	5
177	RESPIRE 1: a phase III placebo-controlled randomised trial of ciprofloxacin dry powder for inhalation in non-cystic fibrosis bronchiectasis. European Respiratory Journal, 2018, 51, 1702052.	3.1	146
178	RESPIRE 2: a phase III placebo-controlled randomised trial of ciprofloxacin dry powder for inhalation in non-cystic fibrosis bronchiectasis. European Respiratory Journal, 2018, 51, 1702053.	3.1	144
179	The independent contribution of <i>Pseudomonas aeruginosa</i> infection to long-term clinical outcomes in bronchiectasis. European Respiratory Journal, 2018, 51, 1701953.	3.1	150
180	<i>Pseudomonas aeruginosa</i> infection and exacerbations in bronchiectasis: more questions than answers. European Respiratory Journal, 2018, 51, 1702497.	3.1	14
181	Bronchiectasis: Phenotyping an Orphan Disease. American Journal of Respiratory and Critical Care Medicine, 2018, 197, 1371-1373.	2.5	6
182	Self-management for bronchiectasis. The Cochrane Library, 2018, 2018, CD012528.	1.5	29
183	Clinical Determinants of Incremental Shuttle Walk Test in Adults with Bronchiectasis. Lung, 2018, 196, 343-349.	1.4	11
184	The Prevalence and Significance of <i>Staphylococcus aureus</i> in Patients with Nonâ€“Cystic Fibrosis Bronchiectasis. Annals of the American Thoracic Society, 2018, 15, 365-370.	1.5	36
185	Ethnicity, socioeconomic status and the severity and course of nonâ€“cystic fibrosis bronchiectasis. Internal Medicine Journal, 2018, 48, 845-850.	0.5	12
186	Characterization of the â€œFrequent Exacerbator Phenotypeâ€“in Bronchiectasis. American Journal of Respiratory and Critical Care Medicine, 2018, 197, 1410-1420.	2.5	215
187	Imaging of Bronchiectasis. , 2018, , 9-26.		0
188	The pharmacological treatment of bronchiectasis. Expert Review of Clinical Pharmacology, 2018, 11, 245-258.	1.3	3

#	ARTICLE	IF	CITATIONS
189	Airway Clearance in Bronchiectasis. , 2018, , 257-284.		4
190	Pseudomonas aeruginosa and Bronchiectasis. , 2018, , 157-180.		1
191	Spanish Guidelines on the Evaluation and Diagnosis of Bronchiectasis in Adults. Archivos De Bronconeumologia, 2018, 54, 79-87.	0.4	57
192	¿Existe un mayor impacto de la tos en la calidad de vida según el pronóstico de bronquiectasias?. Archivos De Bronconeumologia, 2018, 54, 238-239.	0.4	1
193	Non-antimicrobial airway management of non-cystic fibrosis bronchiectasis. Journal of Clinical Tuberculosis and Other Mycobacterial Diseases, 2018, 10, 24-28.	0.6	6
194	Pulmonary Rehabilitation in Bronchiectasis. , 2018, , 285-305.		0
195	Exacerbation of Bronchiectasis. , 2018, , 205-222.		2
198	The Role of Other Bacteria, Fungi, and Viruses in Bronchiectasis. , 2018, , 181-187.		0
199	Long-Term Inhaled Antibiotic Treatment in Bronchiectasis. , 2018, , 223-239.		0
200	Long-Term Oral Antibiotic and Anti-inflammatory Treatment. , 2018, , 241-256.		0
201	Surgical Treatment and Lung Transplantation in Bronchiectasis. , 2018, , 307-324.		0
204	The BRICS (Bronchiectasis Radiologically Indexed CT Score). Chest, 2018, 153, 1177-1186.	0.4	44
205	The Bronchiectasis Severity Index and FACED score for assessment of the severity of bronchiectasis. Pulmonology, 2018, 24, 149-154.	1.0	20
206	Clinical Aspects. , 2018, , 39-49.		0
207	Spanish Guidelines on Treatment of Bronchiectasis in Adults. Archivos De Bronconeumologia, 2018, 54, 88-98.	0.4	107
208	Bronchiectasis: Yet another systemic disease?. Respiriology, 2018, 23, 797-798.	1.3	0
209	Macrolide antibiotics for bronchiectasis. The Cochrane Library, 2018, 2018, CD012406.	1.5	52
210	Does the Impact of Cough on Quality of Life in Bronchiectasis Depend on Prognosis?. Archivos De Bronconeumologia, 2018, 54, 238-239.	0.4	1

#	ARTICLE	IF	CITATIONS
211	<i>Pseudomonas aeruginosa</i> isolation in patients with non-cystic fibrosis bronchiectasis: a retrospective study. <i>BMJ Open</i> , 2018, 8, e014613.	0.8	27
212	Bronchiectasis Exacerbations Are Heart-Breaking. <i>Annals of the American Thoracic Society</i> , 2018, 15, 301-303.	1.5	7
213	Understanding the Role of <i>Staphylococcus aureus</i> in Non-Cystic Fibrosis Bronchiectasis: Where Are We Now?. <i>Annals of the American Thoracic Society</i> , 2018, 15, 310-311.	1.5	5
214	<i>Aspergillus</i> precipitating antibody in patients with <i>Mycobacterium avium</i> complex lung disease: A cross-sectional study. <i>Respiratory Medicine</i> , 2018, 138, 1-6.	1.3	9
215	Investigation of bronchiectasis in severe uncontrolled asthma. <i>Clinical Respiratory Journal</i> , 2018, 12, 1212-1218.	0.6	43
216	Respiratory Infections and Antibiotic Usage in Common Variable Immunodeficiency. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2018, 6, 159-168.e3.	2.0	46
217	The Rationale and Evidence for Use of Inhaled Antibiotics to Control <i>Pseudomonas aeruginosa</i> Infection in Non-cystic Fibrosis Bronchiectasis. <i>Journal of Aerosol Medicine and Pulmonary Drug Delivery</i> , 2018, 31, 121-138.	0.7	25
218	Anxiety and depression in adult outpatients with bronchiectasis: Associations with disease severity and health-related quality of life. <i>Clinical Respiratory Journal</i> , 2018, 12, 1485-1494.	0.6	26
219	Subclinical atherosclerosis in adults with steady-state bronchiectasis: A case-control study. <i>Respiratory Medicine</i> , 2018, 134, 110-116.	1.3	11
220	Normativa sobre la valoración y el diagnóstico de las bronquiectasias en el adulto. <i>Archivos De Bronconeumología</i> , 2018, 54, 79-87.	0.4	71
221	Normativa sobre el tratamiento de las bronquiectasias en el adulto. <i>Archivos De Bronconeumología</i> , 2018, 54, 88-98.	0.4	98
222	Genetic mannose binding lectin deficiency is associated with airway microbiota diversity and reduced exacerbation frequency in COPD. <i>Thorax</i> , 2018, 73, 510-518.	2.7	28
223	Medical management of bronchiectasis. <i>Journal of Thoracic Disease</i> , 2018, 10, S3428-S3435.	0.6	10
225	COPD Assessment Test (CAT) is a Valid and Simple Tool to Measure the Impact of Bronchiectasis on Affected Patients. <i>COPD: Journal of Chronic Obstructive Pulmonary Disease</i> , 2018, 15, 512-519.	0.7	20
226	Bronchiectasis. <i>Nature Reviews Disease Primers</i> , 2018, 4, 45.	18.1	181
227	Quantitative assessment of erector spinae muscles in patients with <i>Mycobacterium avium</i> complex lung disease. <i>Respiratory Medicine</i> , 2018, 145, 66-72.	1.3	26
228	A comprehensive approach to lung function in bronchiectasis. <i>Respiratory Medicine</i> , 2018, 145, 120-129.	1.3	46
229	The European Multicentre Bronchiectasis Audit and Research Collaboration (EMBARC) ERS Clinical Research Collaboration. <i>European Respiratory Journal</i> , 2018, 52, 1802074.	3.1	26

#	ARTICLE	IF	CITATIONS
230	Non-cystic fibrosis bronchiectasis in the elderly: current perspectives. <i>Clinical Interventions in Aging</i> , 2018, Volume 13, 1649-1656.	1.3	9
231	Prognostic Factors in Adult Patients with Non-Cystic Fibrosis Bronchiectasis. <i>Lung</i> , 2018, 196, 691-697.	1.4	6
232	Next-generation sequencing for identifying genetic mutations in adults with bronchiectasis. <i>Journal of Thoracic Disease</i> , 2018, 10, 2618-2630.	0.6	23
233	Validation of the Incremental Shuttle Walk Test as a Clinical End Point in Bronchiectasis. <i>Chest</i> , 2018, 154, 1321-1329.	0.4	8
234	In situ identification of Gram-negative bacteria in human lungs using a topical fluorescent peptide targeting lipid A. <i>Science Translational Medicine</i> , 2018, 10, .	5.8	59
236	Advances in bronchiectasis: endotyping, genetics, microbiome, and disease heterogeneity. <i>Lancet, The</i> , 2018, 392, 880-890.	6.3	247
238	Bronchiectasis: Treatment decisions for pulmonary exacerbations and their prevention. <i>Respirology</i> , 2018, 23, 1006-1022.	1.3	24
239	“The missing ingredient” the patient perspective of health related quality of life in bronchiectasis: a qualitative study. <i>BMC Pulmonary Medicine</i> , 2018, 18, 81.	0.8	28
240	Current and future pharmacotherapy options for non-cystic fibrosis bronchiectasis. <i>Expert Review of Respiratory Medicine</i> , 2018, 12, 569-584.	1.0	8
241	Clinical characteristics and validation of bronchiectasis severity score systems for post-tuberculosis bronchiectasis. <i>Clinical Respiratory Journal</i> , 2018, 12, 2346-2353.	0.6	15
242	Effect of Air Pollution on Exacerbations of Bronchiectasis in Badalona, Spain, 2008–2016. <i>Respiration</i> , 2018, 96, 111-116.	1.2	14
243	Predicting outcomes in bronchiectasis. <i>Pulmonology</i> , 2018, 24, 146-148.	1.0	3
244	Outcomes of lung transplantation in adults with bronchiectasis. <i>BMC Pulmonary Medicine</i> , 2018, 18, 82.	0.8	14
245	US Patient-Centered Research Priorities and Roadmap for Bronchiectasis. <i>Chest</i> , 2018, 154, 1016-1023.	0.4	14
246	Characteristics of patients with bronchoscopy-diagnosed pulmonary Mycobacterium avium complex infection. <i>Journal of Infection and Chemotherapy</i> , 2018, 24, 822-827.	0.8	8
247	The overlap between bronchiectasis and chronic airway diseases: state of the art and future directions. <i>European Respiratory Journal</i> , 2018, 52, 1800328.	3.1	138
248	Patient information, education and self-management in bronchiectasis: facilitating improvements to optimise health outcomes. <i>BMC Pulmonary Medicine</i> , 2018, 18, 80.	0.8	23
249	Aspergillus fumigatus Detection and Risk Factors in Patients with COPD–Bronchiectasis Overlap. <i>International Journal of Molecular Sciences</i> , 2018, 19, 523.	1.8	27

#	ARTICLE	IF	CITATIONS
250	The efficacy of inhaled antibiotics in non-cystic fibrosis bronchiectasis. <i>Expert Review of Respiratory Medicine</i> , 2018, 12, 683-691.	1.0	8
251	Pathogenesis, imaging and clinical characteristics of CF and non-CF bronchiectasis. <i>BMC Pulmonary Medicine</i> , 2018, 18, 79.	0.8	43
252	The association between polypharmacy and medication regimen complexity and antibiotic use in bronchiectasis. <i>International Journal of Clinical Pharmacy</i> , 2018, 40, 1342-1348.	1.0	7
253	Cost of Hospitalizations due to Exacerbation in Patients with Non-Cystic Fibrosis Bronchiectasis. <i>Respiration</i> , 2018, 96, 406-416.	1.2	22
254	A qualitative synthesis of gastro-oesophageal reflux in bronchiectasis: Current understanding and future risk. <i>Respiratory Medicine</i> , 2018, 141, 132-143.	1.3	18
255	Assessing effects of inhaled antibiotics in adults with non-cystic fibrosis bronchiectasis—experiences from recent clinical trials. <i>Expert Review of Respiratory Medicine</i> , 2018, 12, 769-782.	1.0	15
256	Blood Neutrophils Are Reprogrammed in Bronchiectasis. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2018, 198, 880-890.	2.5	52
257	Factors associated with bronchiectasis in patients with uncontrolled asthma; the NOPES score: a study in 398 patients. <i>Respiratory Research</i> , 2018, 19, 43.	1.4	62
258	Pneumonic and non-pneumonic exacerbations in bronchiectasis: Clinical and microbiological differences. <i>Journal of Infection</i> , 2018, 77, 99-106.	1.7	17
259	Arterial stiffness in adults with steady-state bronchiectasis: association with clinical indices and disease severity. <i>Respiratory Research</i> , 2018, 19, 86.	1.4	5
260	Anti-bacterial antibody and T cell responses in bronchiectasis are differentially associated with lung colonization and disease. <i>Respiratory Research</i> , 2018, 19, 106.	1.4	6
261	<i>Proteobacteria</i> community compositions correlate with bronchiectasis severity. <i>International Journal of Tuberculosis and Lung Disease</i> , 2018, 22, 1095-1105.	0.6	21
262	Risk of Bacterial Transmission in Bronchiectasis Outpatient Clinics. <i>Current Pulmonology Reports</i> , 2018, 7, 72-78.	0.5	6
263	Impact of concomitant nontuberculous mycobacteria and <i>Pseudomonas aeruginosa</i> isolates in non-cystic fibrosis bronchiectasis. <i>Infection and Drug Resistance</i> , 2018, Volume 11, 1137-1143.	1.1	19
264	COPD-bronchiectasis overlap syndrome: Are there clinical, physiological and radiological synergistic effects?. <i>Egyptian Journal of Radiology and Nuclear Medicine</i> , 2018, 49, 23-28.	0.3	1
265	Continuous versus intermittent antibiotics for bronchiectasis. <i>The Cochrane Library</i> , 2018, 2018, CD012733.	1.5	8
266	The Matter of the Lung: Quantification of Vascular Substance in Asthma. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2018, 198, 1-2.	2.5	8
267	Immunological corollary of the pulmonary mycobiome in bronchiectasis: the CAMEB study. <i>European Respiratory Journal</i> , 2018, 52, 1800766.	3.1	105

#	ARTICLE	IF	CITATIONS
268	Dual antibiotics for bronchiectasis. The Cochrane Library, 2018, 6, CD012514.	1.5	8
269	The impact of acute air pollution fluctuations on bronchiectasis pulmonary exacerbation: a case-crossover analysis. European Respiratory Journal, 2018, 52, 1702557.	3.1	42
270	Bronchiectasis and Chronic Suppurative Lung Disease. , 2019, , 439-459.e6.		4
272	Treatable traits in acute exacerbations of chronic airway diseases. Chronic Respiratory Disease, 2019, 16, 147997311986795.	1.0	48
273	Brazilian consensus on non-cystic fibrosis bronchiectasis. Jornal Brasileiro De Pneumologia, 2019, 45, e20190122.	0.4	27
274	Galectin-9 Is a Possible Promoter of Immunopathology in Rheumatoid Arthritis by Activation of Peptidyl Arginine Deiminase 4 (PAD-4) in Granulocytes. International Journal of Molecular Sciences, 2019, 20, 4046.	1.8	28
275	Diagnostic evaluation of bronchiectasis. Respiratory Medicine: X, 2019, 1, 100006.	1.4	2
276	Las bronquiectasias: una enfermedad compleja y heterogénea. Archivos De Bronconeumologia, 2019, 55, 427-433.	0.4	16
277	Aetiology and disease severity are among the determinants of quality of life in bronchiectasis. Clinical Respiratory Journal, 2019, 13, 521-529.	0.6	14
278	Lung Transplantation for Cystic Fibrosis and Non-cystic Fibrosis Bronchiectasis: A Single-Center Experience. Transplantation Proceedings, 2019, 51, 2029-2034.	0.3	12
279	Australian adults with bronchiectasis: The first report from the Australian Bronchiectasis Registry. Respiratory Medicine, 2019, 155, 97-103.	1.3	48
280	Antimicrobial peptides, disease severity and exacerbations in bronchiectasis. Thorax, 2019, 74, 835-842.	2.7	43
281	Bronchiectasis: A Complex, Heterogeneous Disease. Archivos De Bronconeumologia, 2019, 55, 427-433.	0.4	7
282	Pregnancy Zone Protein Is Associated with Airway Infection, Neutrophil Extracellular Trap Formation, and Disease Severity in Bronchiectasis. American Journal of Respiratory and Critical Care Medicine, 2019, 200, 992-1001.	2.5	42
283	Acute Effects of Oscillatory PEP and Thoracic Compression on Secretion Removal and Impedance of the Respiratory System in Non-Cystic Fibrosis Bronchiectasis. Respiratory Care, 2019, 64, 818-827.	0.8	13
284	Management of Australian Adults with Bronchiectasis in Tertiary Care: Evidence-Based or Access-Driven?. Lung, 2019, 197, 803-810.	1.4	14
285	Airway morphometry in COPD with bronchiectasis: a view on all airway generations. European Respiratory Journal, 2019, 54, 1802166.	3.1	11
286	Airway clearance services (ACs) in Australia for adults with chronic lung conditions: scoping review of publicly available web-based information. BMC Health Services Research, 2019, 19, 808.	0.9	7

#	ARTICLE	IF	CITATIONS
287	Eradication of <i>Pseudomonas aeruginosa</i> with inhaled colistin in adults with non-cystic fibrosis bronchiectasis. <i>Chronic Respiratory Disease</i> , 2019, 16, 147997311987251.	1.0	15
288	Predicting factors for chronic colonization of <i>Pseudomonas aeruginosa</i> in bronchiectasis. <i>European Journal of Clinical Microbiology and Infectious Diseases</i> , 2019, 38, 2299-2304.	1.3	10
289	Efficacy of inhaled ciprofloxacin agents for the treatment of bronchiectasis: a systematic review and meta-analysis of randomized controlled trials. <i>Therapeutic Advances in Respiratory Disease</i> , 2019, 13, 175346661987593.	1.0	8
290	Noncystic fibrosis bronchiectasis management. <i>Current Opinion in Pulmonary Medicine</i> , 2019, 25, 192-200.	1.2	6
291	Pulmonary rehabilitation for bronchiectasis: if not now, when?. <i>European Respiratory Journal</i> , 2019, 53, 1802474.	3.1	5
293	Vitamin D and disease severity in bronchiectasis. <i>Respiratory Medicine</i> , 2019, 148, 1-5.	1.3	19
294	Mucoid <i>Pseudomonas aeruginosa</i> alters sputum viscoelasticity in patients with non-cystic fibrosis bronchiectasis. <i>Respiratory Medicine</i> , 2019, 154, 40-46.	1.3	10
296	Amikacin exposure and susceptibility of macrolide-resistant <i>Mycobacterium abscessus</i> . <i>ERJ Open Research</i> , 2019, 5, 00154-2018.	1.1	6
297	Clinical Heterogeneity in Bronchiectasis. Recommended Reading from the Singapore Respiratory Medicine Fellows. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2019, 200, 507-509.	2.5	1
298	Pulmonary rehabilitation after exacerbation of bronchiectasis: a pilot randomized controlled trial. <i>BMC Pulmonary Medicine</i> , 2019, 19, 85.	0.8	16
299	Practical approach to establishing pulmonary rehabilitation for people with non-COPD diagnoses. <i>Respirology</i> , 2019, 24, 879-888.	1.3	23
300	Employment of an algorithm of care including chest physiotherapy results in reduced hospitalizations and stability of lung function in bronchiectasis. <i>BMC Pulmonary Medicine</i> , 2019, 19, 82.	0.8	8
301	Prevalence of atopy and allergic rhinitis in patients with adult non-cystic fibrosis bronchiectasis. <i>Turkish Journal of Medical Sciences</i> , 2019, 49, 551-557.	0.4	3
302	Bronchiectasis insanity: Doing the same thing over and over again and expecting different results?. <i>F1000Research</i> , 2019, 8, 293.	0.8	11
303	Chronic Bacterial Infection Prevalence, Risk Factors, and Characteristics: A Bronchiectasis Population-Based Prospective Study. <i>Journal of Clinical Medicine</i> , 2019, 8, 315.	1.0	3
304	Effect of N-acetylcysteine on exacerbations of bronchiectasis (BENE): a randomized controlled trial. <i>Respiratory Research</i> , 2019, 20, 73.	1.4	29
305	Personalised anti-inflammatory therapy for bronchiectasis and cystic fibrosis: selecting patients for controlled trials of neutrophil elastase inhibition. <i>ERJ Open Research</i> , 2019, 5, 00252-2018.	1.1	20
306	Paediatric and adult bronchiectasis: Diagnosis, disease burden and prognosis. <i>Respirology</i> , 2019, 24, 413-422.	1.3	20

#	ARTICLE	IF	CITATIONS
307	Prognostic Value of Frequent Exacerbations in Bronchiectasis: The Relationship With Disease Severity. <i>Archivos De Bronconeumologia</i> , 2019, 55, 81-87.	0.4	3
308	The Effect of Pulmonary Rehabilitation on the Physical Activity Level and General Clinical Status of Patients with Bronchiectasis. <i>Turkish Thoracic Journal</i> , 2019, 20, 30-35.	0.2	13
309	Contemporary Concise Review 2018: Bronchiectasis. <i>Respirology</i> , 2019, 24, 382-389.	1.3	0
310	Hypersegmented airway neutrophils and its association with reduced lung function in adults with obstructive airway disease: an exploratory study. <i>BMJ Open</i> , 2019, 9, e024330.	0.8	18
311	British Thoracic Society Guideline for bronchiectasis in adults. <i>Thorax</i> , 2019, 74, 1-69.	2.7	291
312	The biology of pulmonary exacerbations in bronchiectasis. <i>European Respiratory Review</i> , 2019, 28, 190055.	3.0	48
313	Hot topics and current controversies in non-cystic fibrosis bronchiectasis. <i>Breathe</i> , 2019, 15, 286-295.	0.6	9
314	The microbiome in bronchiectasis. <i>European Respiratory Review</i> , 2019, 28, 190048.	3.0	68
315	Clinical Factors Associated with a Shorter or Longer Course of Antibiotic Treatment in Patients with Exacerbations of Bronchiectasis: A Prospective Cohort Study. <i>Journal of Clinical Medicine</i> , 2019, 8, 1950.	1.0	2
316	Role of New Imaging Capabilities with MRI and CT in the Evaluation of Bronchiectasis. <i>Current Pulmonology Reports</i> , 2019, 8, 166-176.	0.5	1
317	<p>Sputum Exosomal microRNAs Profiling Reveals Critical Pathways Modulated By Pseudomonas aeruginosa Colonization In Bronchiectasis</p>. <i>International Journal of COPD</i> , 2019, Volume 14, 2563-2573.	0.9	7
318	Duration of Antibiotic Therapy in Non-cystic Fibrosis Bronchiectasis. <i>Current Pulmonology Reports</i> , 2019, 8, 160-165.	0.5	3
319	Mortality risk and causes of death in patients with non-cystic fibrosis bronchiectasis. <i>Respiratory Research</i> , 2019, 20, 271.	1.4	37
320	High&intensity inspiratory muscle training in bronchiectasis: A randomized controlled trial. <i>Respirology</i> , 2019, 24, 246-253.	1.3	23
321	Health Perception and Behaviors in Adults With Bronchiectasis. <i>Respiratory Care</i> , 2019, 64, 462-472.	0.8	2
322	Bronchiectasis. <i>Chest</i> , 2019, 155, 825-833.	0.4	26
323	A review of non&cystic fibrosis bronchiectasis in children with a focus on the role of long&term treatment with macrolides. <i>Pediatric Pulmonology</i> , 2019, 54, 487-496.	1.0	11
324	Microbiological Progress in Patients with Bronchial Infection with <i>Pseudomonas aeruginosa</i> Treated with Nebulised Colistin. <i>Respiration</i> , 2019, 97, 501-507.	1.2	2

#	ARTICLE	IF	CITATIONS
325	The clinical impact of <i>Pseudomonas aeruginosa</i> eradication in bronchiectasis in a Dutch referral centre. <i>European Respiratory Journal</i> , 2019, 53, 1802081.	3.1	7
326	Prognostic Value of Frequent Exacerbations in Bronchiectasis: The Relationship With Disease Severity. <i>Archivos De Bronconeumologia</i> , 2019, 55, 81-87.	0.4	37
327	Updated BTS Adult Bronchiectasis Guideline 2018: a multidisciplinary approach to comprehensive care. <i>Thorax</i> , 2019, 74, 1-3.	2.7	110
328	Paediatric and adult bronchiectasis: Monitoring, cross-infection, role of multidisciplinary teams and self-management plans. <i>Respirology</i> , 2019, 24, 115-126.	1.3	18
329	Distinct 'Immunoallergy' of Disease and High Frequencies of Sensitization in Non-Cystic Fibrosis Bronchiectasis. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2019, 199, 842-853.	2.5	57
330	COPD Assessment Test in Bronchiectasis: Minimum Clinically Important Difference and Psychometric Validation. <i>Chest</i> , 2020, 157, 824-833.	0.4	16
331	Physical activity of patients with bronchiectasis compared with healthy counterparts: A cross-sectional study. <i>Heart and Lung: Journal of Acute and Critical Care</i> , 2020, 49, 99-104.	0.8	11
332	Clinical Fingerprinting: A Way to Address the Complexity and Heterogeneity of Bronchiectasis in Practice. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2020, 201, 14-19.	2.5	15
333	How does <i>Pseudomonas aeruginosa</i> affect the progression of bronchiectasis?. <i>Clinical Microbiology and Infection</i> , 2020, 26, 313-318.	2.8	21
334	Relationship between clinical and radiological signs of bronchiectasis in COPD patients: Results from COSYCONET. <i>Respiratory Medicine</i> , 2020, 172, 106117.	1.3	4
335	Bronchiectasis and increased mortality in patients with corticosteroid-dependent severe asthma: a nationwide population study. <i>Therapeutic Advances in Respiratory Disease</i> , 2020, 14, 175346662096303.	1.0	20
336	The Roles of Bacteria and Viruses in Bronchiectasis Exacerbation: A Prospective Study. <i>Archivos De Bronconeumologia</i> , 2020, 56, 621-629.	0.4	9
337	Aetiological diagnosis in new adult outpatients with bronchiectasis: role of predictors derived from real life experience. <i>Respiratory Medicine</i> , 2020, 172, 106090.	1.3	2
339	Bronchiectasis in rheumatoid arthritis. A clinical appraisal. <i>Joint Bone Spine</i> , 2020, 87, 419-424.	0.8	13
340	Repeatability of the 6-min walk test in non-cystic fibrosis bronchiectasis. <i>Scientific Reports</i> , 2020, 10, 19162.	1.6	1
341	Impact of <i>Pseudomonas aeruginosa</i> Infection on Patients with Chronic Inflammatory Airway Diseases. <i>Journal of Clinical Medicine</i> , 2020, 9, 3800.	1.0	63
342	Impact of asthma on bronchiectasis severity and risk of exacerbations. <i>Journal of Asthma</i> , 2022, 59, 469-475.	0.9	17
343	New-onset nontuberculous mycobacterial pulmonary disease in bronchiectasis: tracking the clinical and radiographic changes. <i>BMC Pulmonary Medicine</i> , 2020, 20, 293.	0.8	14

#	ARTICLE	IF	CITATIONS
344	Las bronquiectasias como enfermedad compleja. Open Respiratory Archives, 2020, 2, 226-234.	0.0	2
346	Serum biomarkers in patients with stable and exacerbated COPD–bronchiectasis overlap syndrome. Clinical Respiratory Journal, 2020, 14, 1032-1039.	0.6	3
347	Diagnosis and quantification of bronchiectasis using computed tomography or magnetic resonance imaging: A systematic review. Respiratory Medicine, 2020, 170, 105954.	1.3	16
348	The Role of Epstein-Barr Virus in Adults With Bronchiectasis: A Prospective Cohort Study. Open Forum Infectious Diseases, 2020, 7, ofaa235.	0.4	11
349	Systemic Inflammation during and after Bronchiectasis Exacerbations: Impact of Pseudomonas aeruginosa. Journal of Clinical Medicine, 2020, 9, 2631.	1.0	17
350	<p>Performance of Multidimensional Severity Scoring Systems in Patients with Post–Tuberculosis Bronchiectasis</p>. International Journal of COPD, 2020, Volume 15, 2157-2165.	0.9	8
351	Phase 2 Trial of the DPP-1 Inhibitor Brensocatib in Bronchiectasis. New England Journal of Medicine, 2020, 383, 2127-2137.	13.9	158
352	Pharmacotherapeutic management of bronchial infections in adults: non-cystic fibrosis bronchiectasis and chronic obstructive pulmonary disease. Expert Opinion on Pharmacotherapy, 2020, 21, 1975-1990.	0.9	4
353	Evaluation of disease severity in bronchiectasis using impulse oscillometry. ERJ Open Research, 2020, 6, 00053-2020.	1.1	6
354	Bronchiectasis in Severe Asthma: Does It Make a Difference?. Respiration, 2020, 99, 1136-1144.	1.2	10
355	The Open Challenge of in vitro Modeling Complex and Multi-Microbial Communities in Three-Dimensional Niches. Frontiers in Bioengineering and Biotechnology, 2020, 8, 539319.	2.0	5
356	Cost of hospitalization for bronchiectasis exacerbation in children. Respiriology, 2020, 25, 1250-1256.	1.3	31
357	Measuring airway clearance outcomes in bronchiectasis: a review. European Respiratory Review, 2020, 29, 190161.	3.0	13
358	Serum Desmosine Is Associated with Long-Term All-Cause and Cardiovascular Mortality in Bronchiectasis. American Journal of Respiratory and Critical Care Medicine, 2020, 202, 897-899.	2.5	14
359	The Link between Asthma and Bronchiectasis: State of the Art. Respiration, 2020, 99, 463-476.	1.2	32
360	Evaluation of Droplet Digital Polymerase Chain Reaction (ddPCR) for the Absolute Quantification of Aspergillus species in the Human Airway. International Journal of Molecular Sciences, 2020, 21, 3043.	1.8	19
361	Sputum neutrophil elastase associates with microbiota and <i>Pseudomonas aeruginosa</i> in bronchiectasis. European Respiratory Journal, 2020, 56, 2000769.	3.1	37
362	Real-life experience with high-frequency chest wall oscillation vest therapy in adults with non-cystic fibrosis bronchiectasis. Therapeutic Advances in Respiratory Disease, 2020, 14, 175346662093250.	1.0	13

#	ARTICLE	IF	CITATIONS
363	The radiological diagnosis of bronchiectasis: what's in a name?. <i>European Respiratory Review</i> , 2020, 29, 190120.	3.0	25
364	Aberrant Epithelial Cell Proliferation in Peripheral Airways in Bronchiectasis. <i>Frontiers in Cell and Developmental Biology</i> , 2020, 8, 88.	1.8	7
365	Managing and preventing exacerbation of bronchiectasis. <i>Current Opinion in Infectious Diseases</i> , 2020, 33, 189-196.	1.3	8
366	Infection prevention and chronic disease management in cystic fibrosis and noncystic fibrosis bronchiectasis. <i>Therapeutic Advances in Respiratory Disease</i> , 2020, 14, 175346662090527.	1.0	2
367	Bronchiectasis in the Elderlyâ€”a Disease That Has Not Gone Away. <i>Current Geriatrics Reports</i> , 2020, 9, 19-29.	1.1	1
368	Relationship between Symptoms, Exacerbations, and Treatment Response in Bronchiectasis. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2020, 201, 1499-1507.	2.5	25
369	Is bronchiectasis really a disease?. <i>European Respiratory Review</i> , 2020, 29, 190051.	3.0	10
370	Les bronchectasies dans la polyarthrite rhumatoïde: Ã©valuation clinique. <i>Revue Du Rhumatisme (Edition Francaise)</i> , 2020, 87, 353-358.	0.0	0
371	KMBARC registry: protocol for a multicentre observational cohort study on non-cystic fibrosis bronchiectasis in Korea. <i>BMJ Open</i> , 2020, 10, e034090.	0.8	19
372	Clinical features related to hospital expenses for non-cystic fibrosis bronchiectasis in China. <i>Journal of International Medical Research</i> , 2020, 48, 030006052093161.	0.4	1
373	Sputum neutrophil elastase in bronchiectasis: a Southern European cohort study. <i>European Respiratory Journal</i> , 2020, 56, 2001702.	3.1	15
374	Inhaled antibiotics therapy for stable non-cystic fibrosis bronchiectasis: a meta-analysis. <i>Therapeutic Advances in Respiratory Disease</i> , 2020, 14, 175346662093686.	1.0	11
375	A decade on: Follow-up findings of indigenous children with bronchiectasis. <i>Pediatric Pulmonology</i> , 2020, 55, 975-985.	1.0	15
376	Pulmonary function evaluation in pediatric patients with primary immunodeficiency complicated by bronchiectasis. <i>Journal of Microbiology, Immunology and Infection</i> , 2020, 53, 1014-1020.	1.5	2
377	Etiology and characteristics of patients with bronchiectasis in Taiwan: a cohort study from 2002 to 2016. <i>BMC Pulmonary Medicine</i> , 2020, 20, 45.	0.8	36
379	The association between serum albumin/prealbumin level and disease severity in non-CF bronchiectasis. <i>Clinical and Experimental Pharmacology and Physiology</i> , 2020, 47, 1537-1544.	0.9	9
380	The Roles of Bacteria and Viruses in Bronchiectasis Exacerbation: A Prospective Study. <i>Archivos De Bronconeumologia</i> , 2020, 56, 621-629.	0.4	32
381	Bacterial Community Interactions During Chronic Respiratory Disease. <i>Frontiers in Cellular and Infection Microbiology</i> , 2020, 10, 213.	1.8	70

#	ARTICLE	IF	CITATIONS
382	Bronchiectasis in Primary Antibody Deficiencies: A Multidisciplinary Approach. <i>Frontiers in Immunology</i> , 2020, 11, 522.	2.2	24
383	Clinical impact of cardiovascular disease on patients with bronchiectasis. <i>BMC Pulmonary Medicine</i> , 2020, 20, 101.	0.8	6
385	Association between physical activity and risk of hospitalisation in bronchiectasis. <i>European Respiratory Journal</i> , 2020, 55, 1902138.	3.1	16
386	Metagenomics Reveals a Core Macrolide Resistome Related to Microbiota in Chronic Respiratory Disease. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2020, 202, 433-447.	2.5	58
387	Bronchiectasis Information and Education: a randomised, controlled feasibility trial. <i>Trials</i> , 2020, 21, 331.	0.7	8
388	Patient outcomes associated with post-tuberculosis lung damage in Malawi: a prospective cohort study. <i>Thorax</i> , 2020, 75, 269-278.	2.7	120
389	British Thoracic Society guideline for the use of long-term macrolides in adults with respiratory disease. <i>Thorax</i> , 2020, 75, 370-404.	2.7	31
390	Exacerbations and <i>Pseudomonas aeruginosa</i> colonization are associated with altered lung structure and function in primary ciliary dyskinesia. <i>BMC Pediatrics</i> , 2020, 20, 158.	0.7	16
391	<i>Pseudomonas aeruginosa</i> and lung function decline in patients with bronchiectasis. <i>Clinical Microbiology and Infection</i> , 2021, 27, 428-434.	2.8	36
392	Serum Krebs von den Lungen-6 level in the disease progression and treatment of <i>Mycobacterium avium</i> complex lung disease. <i>Respirology</i> , 2021, 26, 112-119.	1.3	13
393	Association of hospital admission for bronchiectasis with air pollution: A province-wide time-series study in southern China. <i>International Journal of Hygiene and Environmental Health</i> , 2021, 231, 113654.	2.1	13
394	The clinical phenotype of bronchiectasis and its clinical guiding implications. <i>Experimental Biology and Medicine</i> , 2021, 246, 275-280.	1.1	6
395	RIBRON: The Spanish online bronchiectasis registry. Characterization of the first 1912 patients. <i>Archivos De Bronconeumología</i> , 2021, 57, 28-35.	0.4	36
396	The detrimental qualitative and quantitative alterations of circulating endothelial progenitor cells in patients with bronchiectasis. <i>Respiratory Medicine</i> , 2021, 176, 106270.	1.3	2
397	Validation of the Bronchiectasis Impact Measure (BIM): a novel patient-reported outcome measure. <i>European Respiratory Journal</i> , 2021, 57, 2003156.	3.1	14
398	The contribution of <i>Pseudomonas aeruginosa</i> infection to clinical outcomes in bronchiectasis: a prospective cohort study. <i>Annals of Medicine</i> , 2021, 53, 459-469.	1.5	2
399	Respiratory Viruses in Acute Exacerbations of Bronchiectasis. <i>Journal of Korean Medical Science</i> , 2021, 36, e217.	1.1	6
400	RIBRON: el registro español informatizado de bronquiectasias. Caracterización de los primeros 1.912 pacientes. <i>Archivos De Bronconeumología</i> , 2021, 57, 28-35.	0.4	44

#	ARTICLE	IF	CITATIONS
401	Imaging in non-cystic fibrosis bronchiectasis and current limitations. <i>BJR Open</i> , 2021, 3, 20210026.	0.4	4
402	Bronchiectasis severity correlates with outcome in patients with primary antibody deficiency. <i>Thorax</i> , 2021, 76, 1036-1039.	2.7	3
403	<i>Pseudomonas aeruginosa</i> associated with severity of non-cystic fibrosis bronchiectasis measured by the modified bronchiectasis severity score (BSI) and the FACED: The US bronchiectasis and NTM Research Registry (BRR) study. <i>Respiratory Medicine</i> , 2021, 177, 106285.	1.3	7
404	BronchUK: protocol for an observational cohort study and biobank in bronchiectasis. <i>ERJ Open Research</i> , 2021, 7, 00775-2020.	1.1	4
405	Comparative evaluation of expiratory airflow limitation between patients with COPD and BE using IOS. <i>Scientific Reports</i> , 2021, 11, 4524.	1.6	5
406	Comorbidities and mortality risk factors for patients with bronchiectasis. <i>Expert Review of Respiratory Medicine</i> , 2021, 15, 623-634.	1.0	9
407	Favorable Response to Long-Term Azithromycin Therapy in Bronchiectasis Patients with Chronic Airflow Obstruction Compared to Chronic Obstructive Pulmonary Disease Patients without Bronchiectasis. <i>International Journal of COPD</i> , 2021, Volume 16, 855-863.	0.9	2
408	ERS International Congress 2020: highlights from the Respiratory Infections assembly. <i>ERJ Open Research</i> , 2021, 7, 00091-2021.	1.1	1
409	Validity of Self-rating Screening Scales for the Diagnosis of Depression and Anxiety in Adult Patients With Bronchiectasis. <i>Archivos De Bronconeumologia</i> , 2021, 57, 179-185.	0.4	4
410	Detection and Classification of Bronchiectasis Through Convolutional Neural Networks. <i>Journal of Thoracic Imaging</i> , 2022, 37, 100-108.	0.8	9
411	Validity of Self-rating Screening Scales for the Diagnosis of Depression and Anxiety in Adult Patients With Bronchiectasis. <i>Archivos De Bronconeumologia</i> , 2021, 57, 179-185.	0.4	8
412	Personalized approaches to bronchiectasis. <i>Expert Review of Respiratory Medicine</i> , 2021, 15, 477-491.	1.0	2
413	Exacerbations and Changes in Physical Activity and Sedentary Behaviour in Patients with Bronchiectasis after 1 Year. <i>Journal of Clinical Medicine</i> , 2021, 10, 1190.	1.0	4
414	Integrative microbiomics in bronchiectasis exacerbations. <i>Nature Medicine</i> , 2021, 27, 688-699.	15.2	105
415	Diaphragmatic Ultrasound in Non-Cystic Fibrosis Bronchiectasis: Relationship to Clinical Parameters. <i>Ultrasound in Medicine and Biology</i> , 2021, 47, 902-909.	0.7	6
416	Effects of a Mixture of Ivy Leaf Extract and <i>Coptidis</i> rhizome on Patients with Chronic Bronchitis and Bronchiectasis. <i>International Journal of Environmental Research and Public Health</i> , 2021, 18, 4024.	1.2	3
417	Risk factors for <i>Pseudomonas aeruginosa</i> colonization in non-cystic fibrosis bronchiectasis and clinical implications. <i>Respiratory Research</i> , 2021, 22, 132.	1.4	12
418	Prognosis of nontuberculous mycobacterial pulmonary disease according to the method of microbiologic diagnosis. <i>Scientific Reports</i> , 2021, 11, 8036.	1.6	1

#	ARTICLE	IF	CITATIONS
419	Body mass index as a predictor of mortality in bronchiectasis: A nationwide population-based study. <i>Respiratory Medicine</i> , 2021, 180, 106370.	1.3	5
420	Automated Computed Tomography Lung Densitometry in Bronchiectasis Patients. <i>Archivos De Bronconeumologia</i> , 2021, , .	0.4	1
421	Utility of Bronchiectasis severity index (BSI) as prognostic tool in patients with post tubercular bronchiectasis: An experience from a tertiary care hospital in North India. <i>Indian Journal of Tuberculosis</i> , 2021, 68, 261-265.	0.3	1
422	Association of low fat mass with nontuberculous mycobacterial infection in patients with bronchiectasis. <i>Medicine (United States)</i> , 2021, 100, e25193.	0.4	4
423	Aspergillus-related diseases in a cohort of patients with severe asthma: A SANI single-center report. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2021, 9, 2920-2922.e2.	2.0	7
424	Which scoring system is better in association with exercise capacity and health status in noncystic fibrosis bronchiectasis patients?. <i>Turkish Journal of Medical Sciences</i> , 2021, 51, 631-637.	0.4	1
425	Reversible bronchial dilatation in adults. <i>Clinical and Experimental Pharmacology and Physiology</i> , 2021, 48, 966-970.	0.9	5
426	<i>Pseudomonas aeruginosa</i> in bronchiectasis: infection, inflammation, and therapies. <i>Expert Review of Respiratory Medicine</i> , 2021, 15, 649-662.	1.0	19
427	Knowledge, attitudes, and practice about bronchiectasis among general practitioners in four African cities. , 0, 2, 94-100.		2
428	Isolated IgG2 deficiency is an independent risk factor for exacerbations in bronchiectasis. <i>QJM - Monthly Journal of the Association of Physicians</i> , 2022, 115, 292-297.	0.2	2
429	Feasibility of shortening intravenous antibiotic therapy for bronchiectasis based on bacterial load: a proof-of-concept randomised controlled trial. <i>European Respiratory Journal</i> , 2021, 58, 2004388.	3.1	11
430	Chronic Obstructive Pulmonary Disease as a Phenotype of Bronchiectasis for Long-Term Clinical Presentation and Treatment. <i>Medicina (Lithuania)</i> , 2021, 57, 579.	0.8	1
432	The importance of central airway dilatation in patients with bronchiolitis obliterans. <i>ERJ Open Research</i> , 2021, 7, 00123-2021.	1.1	3
434	Management of non-cystic fibrosis bronchiectasis. <i>British Journal of Hospital Medicine (London,)</i> Tj ETQq1 1 0.784314 rgBT /Overlock	0.2	1
435	Sputum procalcitonin: a potential biomarker in stable bronchiectasis. <i>ERJ Open Research</i> , 2021, 7, 00285-2021.	1.1	0
436	T2-High Endotype and Response to Biological Treatments in Patients with Bronchiectasis. <i>Biomedicines</i> , 2021, 9, 772.	1.4	24
437	Diagnosis and Initial Investigation of Bronchiectasis. <i>Seminars in Respiratory and Critical Care Medicine</i> , 2021, 42, 513-524.	0.8	4
438	The Deteriorating Patient: Therapies Including Lung Transplantation. <i>Seminars in Respiratory and Critical Care Medicine</i> , 2021, 42, 623-638.	0.8	0

#	ARTICLE	IF	CITATIONS
439	Bronchiectasis Exacerbations: Definitions, Causes, and Acute Management. <i>Seminars in Respiratory and Critical Care Medicine</i> , 2021, 42, 595-605.	0.8	6
440	<i>Pseudomonas aeruginosa</i> in Bronchiectasis. <i>Seminars in Respiratory and Critical Care Medicine</i> , 2021, 42, 587-594.	0.8	7
441	Differences in Nutritional Status and Inflammatory Biomarkers between Female and Male Patients with Bronchiectasis: A Large-Cohort Study. <i>Biomedicines</i> , 2021, 9, 905.	1.4	5
442	Inhaled Corticosteroid Therapy in Bronchiectasis is Associated with All-Cause Mortality: A Prospective Cohort Study. <i>International Journal of COPD</i> , 2021, Volume 16, 2119-2127.	0.9	10
443	Consensus document for the selection of lung transplant candidates: An update from the International Society for Heart and Lung Transplantation. <i>Journal of Heart and Lung Transplantation</i> , 2021, 40, 1349-1379.	0.3	293
444	Pathophysiology of Bronchiectasis. <i>Seminars in Respiratory and Critical Care Medicine</i> , 2021, 42, 499-512.	0.8	17
445	Chest Computed Tomography Features of Nontuberculous Mycobacterial Pulmonary Disease Versus Asymptomatic Colonization. <i>Journal of Thoracic Imaging</i> , 2021, Publish Ahead of Print, .	0.8	4
446	Common Variable Immunodeficiency and Other Immunodeficiency Syndromes in Bronchiectasis. <i>Seminars in Respiratory and Critical Care Medicine</i> , 2021, 42, 525-536.	0.8	2
447	Heterogeneity of non-cystic-fibrosis bronchiectasis in multiethnic Singapore: A prospective cohort study at a tertiary pulmonology centre. <i>Annals of the Academy of Medicine, Singapore</i> , 2021, 50, 556-565.	0.2	2
448	Mepolizumab effectiveness in patients with severe eosinophilic asthma and co-presence of bronchiectasis: A real-world retrospective pilot study. <i>Respiratory Medicine</i> , 2021, 185, 106491.	1.3	33
449	Chronic Obstructive Pulmonary Disease Is Associated With Decreased Quality of Life in Bronchiectasis Patients: Findings From the KMBARC Registry. <i>Frontiers in Medicine</i> , 2021, 8, 722124.	1.2	5
450	High Frequency of Allergic Bronchopulmonary Aspergillosis in Bronchiectasis-COPD Overlap. <i>Chest</i> , 2022, 161, 40-53.	0.4	8
451	Impact of non-cystic fibrosis bronchiectasis on critically ill patients in Korea: a retrospective observational study. <i>Scientific Reports</i> , 2021, 11, 15757.	1.6	1
452	Serum hepatocyte growth factor as a predictor of disease severity and future exacerbations in patients with non-cystic fibrosis bronchiectasis. <i>Respiratory Medicine</i> , 2021, 185, 106505.	1.3	2
453	Exploring factors associated with acquisition and chronicity of infection in bronchiectasis: A population-based study. <i>Respiratory Medicine</i> , 2021, 185, 106487.	1.3	1
454	The sputum microbiome and clinical outcomes in patients with bronchiectasis: a prospective observational study. <i>Lancet Respiratory Medicine</i> , 2021, 9, 885-896.	5.2	63
455	Phenotypic Clustering in Non-Cystic Fibrosis Bronchiectasis Patients: The Role of Eosinophils in Disease Severity. <i>International Journal of Environmental Research and Public Health</i> , 2021, 18, 8431.	1.2	21
456	Neutrophil extracellular traps, disease severity, and antibiotic response in bronchiectasis: an international, observational, multicohort study. <i>Lancet Respiratory Medicine</i> , 2021, 9, 873-884.	5.2	99

#	ARTICLE	IF	CITATIONS
457	Special considerations for pulmonary rehabilitation in conditions other than COPD. , 2021, , 145-164.		3
458	Meta-analysis of efficacy and safety of inhaled ciprofloxacin in non-cystic fibrosis bronchiectasis patients. Internal Medicine Journal, 2021, 51, 1505-1512.	0.5	2
459	Being Underweight Increases the Risk of Non-Cystic Fibrosis Bronchiectasis in the Young Population: A Nationwide Population-Based Study. Nutrients, 2021, 13, 3206.	1.7	8
460	Clinical Characteristics of Patients with Post-Tuberculosis Bronchiectasis: Findings from the KMBARC Registry. Journal of Clinical Medicine, 2021, 10, 4542.	1.0	9
461	Totally antibiotic resistance Pseudomonas aeruginosa isolated from patients with blood stream infection. Applied Nanoscience (Switzerland), 0, , 1.	1.6	0
462	Do Redox Balance and Inflammatory Events Take Place in Mild Bronchiectasis? A Hint to Clinical Implications. Journal of Clinical Medicine, 2021, 10, 4534.	1.0	5
463	Prevalence of depression and its associated factors in bronchiectasis: findings from KMBARC registry. BMC Pulmonary Medicine, 2021, 21, 306.	0.8	3
464	Bronchoscopic airway clearance therapy for acute exacerbations of bronchiectasis. EBioMedicine, 2021, 72, 103587.	2.7	4
465	Factors associated with "Frequent Exacerbator" phenotype in children with bronchiectasis: The first report on children from the Australian Bronchiectasis Registry. Respiratory Medicine, 2021, 188, 106627.	1.3	7
466	Prognostic utility of various multidimensional grading scales among Saudi patients with bronchiectasis. Respiratory Medicine and Research, 2021, 80, 100843.	0.4	0
468	Bronchiectasis in Childhood (Including PBB). , 2022, , 208-228.		0
469	C-Reactive Protein Concentration in Steady-State Bronchiectasis: Prognostic Value of Future Severe Exacerbations. Data From the Spanish Registry of Bronchiectasis (RIBRON). Archivos De Bronconeumologia, 2021, 57, 21-27.	0.4	30
470	Thrombocytosis during Stable State Predicts Mortality in Bronchiectasis. Annals of the American Thoracic Society, 2021, 18, 1316-1325.	1.5	6
471	C-Reactive Protein Concentration in Steady-State Bronchiectasis: Prognostic Value of Future Severe Exacerbations. Data From the Spanish Registry of Bronchiectasis (RIBRON). Archivos De Bronconeumologia, 2021, 57, 21-27.	0.4	35
472	ERS International Congress 2020: highlights from the Paediatric Assembly. ERJ Open Research, 2021, 7, 00893-2020.	1.1	2
473	Severity assessment of non-cystic fibrosis bronchiectasis by the FACED score. , 0, 2, 42-48.		0
474	Serum albumin is a predictor of respiratory hospitalization in patients with bronchiectasis. Chronic Respiratory Disease, 2021, 18, 147997312110175.	1.0	4
475	Prognostic performance of the FACED score and bronchiectasis severity index in bronchiectasis: a systematic review and meta-analysis. Bioscience Reports, 2020, 40, .	1.1	7

#	ARTICLE	IF	CITATIONS
476	Tapering analysis of airways with bronchiectasis. , 2018, , .		4
477	How do we know what works? Clinical trial end-points and quality of life assessment. , 0, , 99-132.		2
478	Phenotypes and endotypes. , 0, , 133-152.		1
479	The overlap with bronchiectasis. , 0, , 96-108.		2
481	Whatâ€™s new in the management of adult bronchiectasis?. F1000Research, 2017, 6, 527.	0.8	3
482	Capsaicin Cough Sensitivity and the Association with Clinical Parameters in Bronchiectasis. PLoS ONE, 2014, 9, e113057.	1.1	15
483	Impacts of Co-Existing Chronic Rhinosinusitis on Disease Severity and Risks of Exacerbations in Chinese Adults with Bronchiectasis. PLoS ONE, 2015, 10, e0137348.	1.1	20
484	Comparison of two prognostic scores (BSI and FACED) in a Spanish cohort of adult patients with bronchiectasis and improvement of the FACED predictive capacity for exacerbations. PLoS ONE, 2017, 12, e0175171.	1.1	32
485	Nutrition and Markers of Disease Severity in Patients With Bronchiectasis. Chronic Obstructive Pulmonary Diseases (Miami, Fla), 2020, 7, 390-403.	0.5	3
486	The disease burden of bronchiectasis in comparison with chronic obstructive pulmonary disease: a national database study in Korea. Annals of Translational Medicine, 2019, 7, 770-770.	0.7	19
487	Evidence of Inhaled Tobramycin in Non-Cystic Fibrosis Bronchiectasis. Open Respiratory Medicine Journal, 2015, 9, 30-36.	1.3	19
488	Assessment of the Non-Cystic Fibrosis Bronchiectasis Severity: The FACED Score vs the Bronchiectasis Severity Index. Open Respiratory Medicine Journal, 2015, 9, 46-51.	1.3	35
490	Characterization of the severity of dyspnea in patients with bronchiectasis: correlation with clinical, functional, and tomographic aspects. Jornal Brasileiro De Pneumologia, 2020, 46, e20190162-e20190162.	0.4	6
491	FACTORS AFFECTING THE FREQUENCY OF EXACERBATIONS IN ADULT PATIENTS WITH BRONCHIECTASIS. WiadomoÅci Lekarskie, 2020, 73, 1717-1722.	0.1	1
492	Bronchodilator response in adults with bronchiectasis: correlation with clinical parameters and prognostic implications. Journal of Thoracic Disease, 2016, 8, 14-23.	0.6	18
493	Interstitial pneumonia associated to peginterferon alpha-2a: A focus on lung function. Lung India, 2016, 33, 228.	0.3	3
494	The Saudi Thoracic Society guidelines for diagnosis and management of noncystic fibrosis bronchiectasis. Annals of Thoracic Medicine, 2017, 12, 135.	0.7	37
495	The effect of the presence and severity of bronchiectasis on the respiratory functions, exercise capacity, dyspnea perception, and quality of life in patients with chronic obstructive pulmonary disease. Annals of Thoracic Medicine, 2020, 15, 26.	0.7	6

#	ARTICLE	IF	CITATIONS
496	Vitamin D Deficiency and Radiological Findings in Adult Non-Cystic Fibrosis Bronchiectasis. Turkish Thoracic Journal, 2020, 21, 87-92.	0.2	2
497	Heterogeneity of treatment response in bronchiectasis clinical trials. European Respiratory Journal, 2022, 59, 2100777.	3.1	21
498	The clinical impact of self-reported symptoms of chronic rhinosinusitis in people with bronchiectasis. Immunity, Inflammation and Disease, 2021, , .	1.3	3
499	Cardiovascular Events during and after Bronchiectasis Exacerbations and Long-Term Mortality. Chest, 2021, , .	0.4	0
500	The Lung Microbiome during Health and Disease. International Journal of Molecular Sciences, 2021, 22, 10872.	1.8	72
501	Residual volume/total lung capacity ratio confers limited additive significance to lung clearance index for assessment of adults with bronchiectasis. PLoS ONE, 2017, 12, e0183779.	1.1	4
502	Non-CF bronchiectasis of adults: short review for clinical practice. Position paper of Board of disease with bronchial obstruction Czech Pulmonological and Phthiaseological Society Czech Medical Association of J. E. Purkyne. Vnitřní Lekarství, 2017, 63, 821-833.	0.1	0
503	Gastro Oesophageal Reflux and Bronchiectasis. , 2018, , 175-186.		0
504	Case of Missing Plastic: Foreign Body Bronchiectasis. Cureus, 2018, 10, e2974.	0.2	3
505	PREDICTION OF THE BRONCHIECTASIS DEVELOPMENT RISK IN CHILDREN WITH CYSTIC FIBROSIS. Inter Collegas, 2019, 5, 171-175.	0.0	0
506	Intermittent prophylactic antibiotics for bronchiectasis. The Cochrane Library, 0, , .	1.5	1
507	Current approaches to pharmacological treatment of adult patients with bronchiectasis. Pulmonologiya, 2019, 29, 71-86.	0.2	1
508	BronĖiektazili Hastalarda Mortalite ve Morbiditeyi Etkileyen FaktĖrler. Kocatepe TĖp Dergisi, 2019, 20, 83-90.	0.0	0
509	Non Cystic Fibrosis Bronchiectasis-new clinical approach, management of treatment and pulmonary rehabilitation. Balneo Research Journal, 2019, 10, 103-113.	0.4	0
511	Dilataciones de los bronquios del adulto. EMC - Tratado De Medicina, 2019, 23, 1-8.	0.0	0
512	Reproducibility of an airway tapering measurement in computed tomography with application to bronchiectasis. Journal of Medical Imaging, 2019, 6, 1.	0.8	1
513	Effects of A Long-Term Use of Carbocysteine on Frequency and Duration of Exacerbations in Patients with Bronchiectasis. Open Access Macedonian Journal of Medical Sciences, 2019, 7, 4030-4035.	0.1	2
514	Clinical Approach to Non-cystic fibrosis Bronchiectasis Based on Recent Clinical Guideline. Korean Journal of Medicine, 2020, 95, 141-150.	0.1	2

#	ARTICLE	IF	CITATIONS
515	Clinical impact of depression and anxiety in patients with non-cystic fibrosis bronchiectasis. <i>Tuberkuloz Ve Toraks</i> , 2020, 68, 103-111.	0.2	2
516	Neutrophils to Lymphocyte Ratio as a Biomarker in Bronchiectasis Exacerbation: A Retrospective Study. <i>Cureus</i> , 2020, 12, e9728.	0.2	3
517	Update on pharmacotherapy for adult bronchiectasis. <i>Journal of the Korean Medical Association</i> , 2020, 63, 486-492.	0.1	1
518	Bronchiectasis severity assessment on predicting hospital readmission: a single-center prospective cohort study. <i>Chinese Medical Journal</i> , 2021, 134, 492-494.	0.9	0
519	The Isoform GC1f of the Vitamin D Binding Protein Is Associated with Bronchiectasis Severity. <i>Biomedicines</i> , 2021, 9, 1573.	1.4	3
520	Clinical Impact of the Bronchiectasis with Chronic Bronchitis Symptoms in COPD: Analysis of a Longitudinal Cohort. <i>International Journal of COPD</i> , 2021, Volume 16, 2997-3008.	0.9	4
521	Impact of Bronchiectasis on Postoperative Pulmonary Complications after Extra-Pulmonary Surgery in Patients with Airflow Limitation. <i>Journal of Korean Medical Science</i> , 2020, 35, e80.	1.1	0
522	A study of the psychometric properties of the Brazilianâ€“Portuguese version of Bronchiectasis Health Questionnaire. <i>Pulmonology</i> , 2020, , .	1.0	1
523	THE EFFECTIVENESS OF THE SALBUTAMOL AND HYPERTONIC SODIUM CHLORIDE SOLUTION WITH SODIUM HYALURONATE COMBINATION IN THE TREATMENT OF PATIENTS WITH BRONCHIECTASIS. <i>Asthma and Allergy</i> , 2020, , 35-41.	0.0	0
524	Risk of Severe Bleeding With Extended Rivaroxaban to Prevent Venous Thromboembolism in Acute Medically Ill Patients With Bronchiectasis. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2021, 27, 107602962110533.	0.7	2
525	Telemedicine and Remote Monitoring as an Adjunct to Medical Management of Bronchiectasis. <i>Life</i> , 2021, 11, 1196.	1.1	5
526	Managing Bronchiectasis: 13 Years of Experience from Sputum to Lung Transplantation. <i>Turkish Thoracic Journal</i> , 2020, 21, 261-265.	0.2	0
527	Inhaled antibiotics in chronic airway infections. , 0, , 57-79.		0
528	Management of frequently exacerbating patients. , 0, , 300-311.		0
529	Comorbidities and their impact. , 0, , 45-61.		1
530	Defining severe bronchiectasis. , 0, , 62-81.		0
531	Non-cystic fibrosis bronchiectasis: definition, severity and impact of pulmonary exacerbations. , 0, , 38-57.		0
532	Nontuberculous mycobacteria infections in patients receiving immunosuppressive agents. , 0, , 238-253.		0

#	ARTICLE	IF	CITATIONS
533	Non-cystic fibrosis bronchiectasis: treatment and prevention of pulmonary exacerbations. , 0 , 181-198.		0
534	Antibiotic management and resistance. , 0 , 312-330.		0
535	Site of care and multidisciplinary approach. , 0 , 353-370.		2
536	Future directions: the next 10 years in research. , 0 , 371-387.		0
539	Microbiological profile of sputum in stable adult patients with bronchiectasis in the Dnipro region of Ukraine. <i>Medicni Perspektivi</i> , 2020, 25, 104-110.	0.1	0
540	Coronary Artery Calcification on Thoracic Computed Tomography Is an Independent Predictor of Mortality in Patients With Bronchiectasis. <i>Journal of Thoracic Imaging</i> , 2021, 36, 166-173.	0.8	4
541	Chronic rhinosinusitis in non-cystic fibrosis bronchiectasis and primary ciliary dyskinesia. , 0 , 148-161.		2
542	Bronchiectasis. <i>Clinical Evidence</i> , 2015, 2015, .	0.2	5
543	Effect of airway <i>Pseudomonas aeruginosa</i> isolation and infection on steady-state bronchiectasis in Guangzhou, China. <i>Journal of Thoracic Disease</i> , 2015, 7, 625-36.	0.6	11
545	Primary immunodeficiency disease: a cost-utility analysis comparing intravenous vs subcutaneous immunoglobulin replacement therapy in Australia. <i>Blood Transfusion</i> , 2020, 18, 96-105.	0.3	2
546	Surgical treatment of bronchiectasis: Our 23 years of experience. <i>Turkish Journal of Thoracic and Cardiovascular Surgery</i> , 2020, 28, 629-637.	0.2	0
547	Infection prevention in general medical wards: A call to action. <i>African Journal of Thoracic and Critical Care Medicine</i> , 2019, 25, .	0.3	0
548	Quality of life and its determinants in patients with noncystic fibrosis bronchiectasis. <i>Journal of Research in Medical Sciences</i> , 2021, 26, 27.	0.4	2
549	Predicting mortality in non-cystic fibrosis bronchiectasis patients using distance-saturation product. <i>Annals of Medicine</i> , 2021, 53, 2034-2040.	1.5	1
550	Antibioterapia inhalada en paciente con bronquiectasias pulmonares e infecci3n bronquial. <i>Revista De Investigaci3n Y Educaci3n En Ciencias De La Salud (RIECS)</i> , 2021, 6, 4-10.	0.0	0
551	Rationale and Clinical Use of Bronchodilators in Adults with Bronchiectasis. <i>Drugs</i> , 2022, 82, 1-13.	4.9	12
552	Endobronchial Therapy With Gentamicin and Dexamethasone After Airway Clearance by Bronchoscopy in Exacerbation of Non-Cystic Fibrosis Bronchiectasis: A Real-World Observational Study. <i>Frontiers in Pharmacology</i> , 2021, 12, 773241.	1.6	0
553	Dysregulation of prostaglandins, leukotrienes and lipoxin A₄ in bronchiectasis. <i>Thorax</i> , 2022, 77, 960-967.	2.7	2

#	ARTICLE	IF	CITATIONS
554	Type 2-High Severe Asthma with and without Bronchiectasis: A Prospective Observational Multicentre Study. <i>Journal of Asthma and Allergy</i> , 2021, Volume 14, 1441-1452.	1.5	21
555	Developing a Diagnostic Bundle for Bronchiectasis in South Korea: A Modified Delphi Consensus Study. <i>Tuberculosis and Respiratory Diseases</i> , 2022, 85, 56-66.	0.7	8
556	Bronchiektasen: Vielfach unterschätzt. , 0, , .		0
557	Decreased Systemic and Airway Sirtuin 1 Expression in Adults With Bronchiectasis. <i>Frontiers in Medicine</i> , 2021, 8, 768770.	1.2	3
558	The effect of maintenance azithromycin on radiological features in patients with bronchiectasis - Analysis from the BAT randomized controlled trial. <i>Respiratory Medicine</i> , 2022, 192, 106718.	1.3	3
559	Effects of Pleuran (Î2-glucan from <i>Pleurotus ostreatus</i>) Supplementation on Incidence and Duration of Bronchiectasis Exacerbations. <i>Open Access Macedonian Journal of Medical Sciences</i> , 2020, 8, 906-912.	0.1	1
560	Surgical treatment of bronchiectasis: Our 23 years of experience. <i>Turkish Journal of Thoracic and Cardiovascular Surgery</i> , 2020, 28, 629-637.	0.2	1
561	Outcomes and survival following lung transplantation in non-cystic fibrosis bronchiectasis. <i>ERJ Open Research</i> , 2022, 8, 00607-2021.	1.1	3
562	Predictive Factors for and Complications of Bronchiectasis in Common Variable Immunodeficiency Disorders. <i>Journal of Clinical Immunology</i> , 2022, 42, 572-581.	2.0	5
563	Intermittent prophylactic antibiotics for bronchiectasis. <i>The Cochrane Library</i> , 2022, 2022, CD013254.	1.5	4
564	The Predictive Role of Psychological Status and Disease Severity Indexes on Quality of Life Among Patients with Non-CF Bronchiectasis. , 2022, 23, 17-24.		0
565	Respiratory and Peripheral Muscle Weakness and Body Composition Abnormalities in Non-Cystic Fibrosis Bronchiectasis Patients: Gender Differences. <i>Biomedicines</i> , 2022, 10, 334.	1.4	7
566	Systemic Inflammatory Biomarkers Define Specific Clusters in Patients with Bronchiectasis: A Large-Cohort Study. <i>Biomedicines</i> , 2022, 10, 225.	1.4	4
568	Influence of Comorbidities and Airway Clearance on Mortality and Outcomes of Patients With Severe Bronchiectasis Exacerbations in Taiwan. <i>Frontiers in Medicine</i> , 2021, 8, 812775.	1.2	10
569	Psychometric Validation of the German Translation of the Quality of Life Questionnaire-Bronchiectasis (QOL-B)â€”Data from the German Bronchiectasis Registry PROGNOSIS. <i>Journal of Clinical Medicine</i> , 2022, 11, 441.	1.0	1
570	European Respiratory Society Guidelines for the Management of Bronchiectasis in Children and Adolescents. <i>US Respiratory & Pulmonary Diseases</i> , 2021, 6, 8.	0.2	0
571	The Perceptions of Telehealth Physiotherapy for People with Bronchiectasis during a Global Pandemicâ€”A Qualitative Study. <i>Journal of Clinical Medicine</i> , 2022, 11, 1315.	1.0	2
572	The Role of Impulse Oscillometry in Evaluating Disease Severity and Predicting the Airway Reversibility in Patients With Bronchiectasis. <i>Frontiers in Medicine</i> , 2022, 9, .	1.2	5

#	ARTICLE	IF	CITATIONS
573	Profile of Clinical and Analytical Parameters in Bronchiectasis Patients during the COVID-19 Pandemic: A One-Year Follow-Up Pilot Study. <i>Journal of Clinical Medicine</i> , 2022, 11, 1727.	1.0	3
574	Improving Care For People With Bronchiectasis: Opportunities And Challenges Highlighted From Service Evaluation. <i>Internal Medicine Journal</i> , 2022, , .	0.5	1
575	Efficacy of <i>N</i> -acetylcysteine on idiopathic or postinfective non-cystic fibrosis bronchiectasis: a systematic review and meta-analysis protocol. <i>BMJ Open</i> , 2022, 12, e053625.	0.8	2
576	Diagnosis and Evaluation of Bronchiectasis. <i>Clinics in Chest Medicine</i> , 2022, 43, 7-22.	0.8	7
577	Radiology of Bronchiectasis. <i>Clinics in Chest Medicine</i> , 2022, 43, 47-60.	0.8	3
578	Non-cardiac Manifestations in Adult Patients With Mucopolysaccharidosis. <i>Frontiers in Cardiovascular Medicine</i> , 2022, 9, 839391.	1.1	3
579	Bronchiectasis from 2012 to 2022. <i>Clinics in Chest Medicine</i> , 2022, 43, 1-6.	0.8	5
580	Bronchiectasis and Chronic Obstructive Pulmonary Disease Overlap Syndrome. <i>Clinics in Chest Medicine</i> , 2022, 43, 61-70.	0.8	6
581	Risk Factors Associated with Impairment in Pulmonary Diffusing Capacity among Patients with Noncystic Fibrosis Bronchiectasis. <i>Canadian Respiratory Journal</i> , 2022, 2022, 1-10.	0.8	1
582	Investigation of drug regimens and treatment outcome in patients with <i>Mycobacterium Simiae</i> : a systematic review. <i>Expert Review of Anti-Infective Therapy</i> , 2022, 20, 1015-1023.	2.0	0
583	Precision medicine in Bronchiectasis. <i>Breathe</i> , 2021, 17, 210119.	0.6	9
584	Less is more? Antibiotic treatment duration for exacerbations of bronchiectasis. <i>European Respiratory Journal</i> , 2021, 58, 2101416.	3.1	2
585	Correlation between clinical-functional parameters and number of lobes involved in non-cystic fibrosis bronchiectasis. <i>Multidisciplinary Respiratory Medicine</i> , 2021, 16, 791.	0.6	2
586	Impacts of Nontuberculous Mycobacteria Isolates in Non-cystic Fibrosis Bronchiectasis: A 16-Year Cohort Study in Taiwan. <i>Frontiers in Microbiology</i> , 2022, 13, 868435.	1.5	5
587	Endotyping Chronic Obstructive Pulmonary Disease, Bronchiectasis, and the "Chronic Obstructive Pulmonary Disease-Bronchiectasis Association". <i>American Journal of Respiratory and Critical Care Medicine</i> , 2022, 206, 417-426.	2.5	29
588	Sputum neutrophil elastase and its relation to pediatric bronchiectasis severity: A cross-sectional study. <i>Health Science Reports</i> , 2022, 5, e581.	0.6	4
589	Bronchiectasis in Low-Dose CT Screening for Lung Cancer. <i>Radiology</i> , 2022, 304, 437-447.	3.6	8
590	COPD and asthma overlap with bronchiectasis. , 0, , 167-185.		0

#	ARTICLE	IF	CITATIONS
599	Mycobacterium avium complex infected cells promote growth of the pathogen <i>Pseudomonas aeruginosa</i> . <i>Microbial Pathogenesis</i> , 2022, 166, 105549.	1.3	1
600	Identification of a novel drug-resistant community-acquired <i>Nocardia</i> spp. in a patient with bronchiectasis. <i>Emerging Microbes and Infections</i> , 2022, , 1-54.	3.0	4
601	Impact of chronic co-infection in pulmonary Mycobacterium avium complex disease after treatment initiation. <i>BMC Pulmonary Medicine</i> , 2022, 22, 157.	0.8	2
602	Primary immunodeficiency disease: a cost-utility analysis comparing intravenous vs subcutaneous immunoglobulin replacement therapy in Australia. <i>Blood Transfusion</i> , 2019, , 1-10.	0.3	6
605	Quality of life and its determinants in patients with noncystic fibrosis bronchiectasis. <i>Journal of Research in Medical Sciences</i> , 2021, 26, 27.	0.4	5
607	Blood Neutrophil Counts Define Specific Clusters of Bronchiectasis Patients: A Hint to Differential Clinical Phenotypes. <i>Biomedicines</i> , 2022, 10, 1044.	1.4	7
608	High Adherence, Microbiological Control and Reduced Exacerbations in Patients With Non-Cystic Fibrosis Bronchiectasis Treated With Nebulised Colistin. A Prospective Observational Study. <i>Archivos De Bronconeumologia</i> , 2022, 58, 834-836.	0.4	4
609	The respiratory tract microbiome: moving from correlation to causation. <i>European Respiratory Journal</i> , 2022, 59, 2103079.	3.1	5
610	Shortened Telomere Length in Sputum Cells of Bronchiectasis Patients is Associated with Dysfunctional Inflammatory Pathways. <i>Lung</i> , 2022, 200, 401-407.	1.4	3
611	Chest wall muscle mass depletion is related to certain pulmonary functions and diseases in patients with bronchiectasis. <i>Chronic Respiratory Disease</i> , 2022, 19, 147997312211055.	1.0	1
612	Bronchodilators in bronchiectasis: there is light but it is still too dim. <i>European Respiratory Journal</i> , 2022, 59, 2103127.	3.1	2
614	In bronchiectasis, poor physical capacity correlates with poor quality of life. <i>European Clinical Respiratory Journal</i> , 2022, 9, .	0.7	4
615	Impact of Chronic Bronchial Infection by <i>Staphylococcus aureus</i> on Bronchiectasis. <i>Journal of Clinical Medicine</i> , 2022, 11, 3960.	1.0	4
616	Serum Fibrinogen as a Biomarker for Disease Severity and Exacerbation in Patients with Non-Cystic Fibrosis Bronchiectasis. <i>Journal of Clinical Medicine</i> , 2022, 11, 3948.	1.0	3
617	Correlation among clinical, functional and morphological indexes of the respiratory system in non-cystic fibrosis bronchiectasis patients. <i>PLoS ONE</i> , 2022, 17, e0269897.	1.1	2
618	Clinical characteristics, radiological features, and disease severity of bronchiectasis according to the spirometric pattern. <i>Scientific Reports</i> , 2022, 12, .	1.6	2
619	Can Leukotriene Receptor Antagonist Therapy Improve the Control of Patients with Severe Asthma on Biological Therapy and Coexisting Bronchiectasis? A Pilot Study. <i>Journal of Clinical Medicine</i> , 2022, 11, 4702.	1.0	5
620	Response to inhaled ceftazidime in patients with non-cystic fibrosis bronchiectasis and chronic bronchial infection unrelated to <i>Pseudomonas aeruginosa</i> . <i>Clinical Respiratory Journal</i> , 0, , .	0.6	3

#	ARTICLE	IF	CITATIONS
621	Bronchiectasis – A Clinical Review. <i>New England Journal of Medicine</i> , 2022, 387, 533-545.	13.9	31
622	Family case studies: absence of <i>Pseudomonas aeruginosa</i> transmission in bronchiectasis. <i>ERJ Open Research</i> , 2022, 8, 00280-2022.	1.1	2
623	Prevalence of chronic rhinosinusitis and its relating factors in patients with bronchiectasis: findings from KMBARC registry. <i>Korean Journal of Internal Medicine</i> , 0, , .	0.7	3
624	A systematic review of lung clearance index in non-cystic fibrosis, non-primary ciliary dyskinesia bronchiectasis. <i>Respiratory Medicine</i> , 2022, 201, 106937.	1.3	0
625	In-person and online application of the Bronchiectasis Health Questionnaire: are they interchangeable?. <i>Jornal Brasileiro De Pneumologia</i> , 0, , e20220075.	0.4	0
626	Practical tips in bronchiectasis for Primary Care. <i>Npj Primary Care Respiratory Medicine</i> , 2022, 32, .	1.1	3
627	The Study of Correlation Between Bronchiectasis Severity Index and FACED Score for Assessment of Severity of Bronchiectasis. <i>National Journal of Community Medicine</i> , 2022, 13, 619-623.	0.1	0
628	Pathophysiology of Chronic Bronchial Infection in Bronchiectasis. <i>Archivos De Bronconeumologia</i> , 2023, 59, 101-108.	0.4	10
629	Targeted AntiBiotics for Chronic pulmonary diseases (TARGET ABC): can targeted antibiotic therapy improve the prognosis of <i>Pseudomonas aeruginosa</i> -infected patients with chronic pulmonary obstructive disease, non-cystic fibrosis bronchiectasis, and asthma? A multicenter, randomized, controlled, open-label trial. <i>Trials</i> , 2022, 23, .	0.7	1
630	<i>Neisseria</i> species as pathobionts in bronchiectasis. <i>Cell Host and Microbe</i> , 2022, 30, 1311-1327.e8.	5.1	17
631	Patient perspectives of airway clearance techniques in bronchiectasis. <i>Physiotherapy Theory and Practice</i> , 2024, 40, 505-515.	0.6	4
632	Approach to Etiological Diagnosis and Initial Management. <i>Respiratory Medicine</i> , 2022, , 117-151.	0.1	0
633	Challenges and Considerations for Clinical Trials Design in Bronchiectasis. <i>Respiratory Medicine</i> , 2022, , 199-209.	0.1	0
634	Acute Exacerbations of Bronchiectasis and the Airway Microbiology. <i>Respiratory Medicine</i> , 2022, , 175-190.	0.1	0
635	Peripheral Neutrophil-to-Lymphocyte Ratio in Bronchiectasis: A Marker of Disease Severity. <i>Biomolecules</i> , 2022, 12, 1399.	1.8	4
636	Inhaled Corticosteroids in Adults with Non-cystic Fibrosis Bronchiectasis: From Bench to Bedside. A Narrative Review. <i>Drugs</i> , 2022, 82, 1453-1468.	4.9	12
637	Clinical outcomes and prognostic factors of bronchiectasis rheumatoid overlap syndrome: A multi-institution cohort study. <i>Frontiers in Medicine</i> , 0, 9, .	1.2	1
638	Clinical outcomes of bronchiectasis in India: data from the EMBARC/Respiratory Research Network of India registry. <i>European Respiratory Journal</i> , 2023, 61, 2200611.	3.1	9

#	ARTICLE	IF	CITATIONS
639	Association between exercise and risk of cardiovascular diseases in patients with non-cystic fibrosis bronchiectasis. <i>Respiratory Research</i> , 2022, 23, .	1.4	6
640	High-Resolution Computed Tomography of Fibrotic Interstitial Lung Disease. <i>Seminars in Respiratory and Critical Care Medicine</i> , 0, , .	0.8	0
641	A truncated mutation of MucA in <i>Pseudomonas aeruginosa</i> from a bronchiectasis patient affects T3SS expression and inflammasome activation. <i>Acta Biochimica Et Biophysica Sinica</i> , 2022, 54, 1740-1747.	0.9	1
642	Bronchiectasis exacerbation: a narrative review of causes, risk factors, management and prevention. <i>Annals of Translational Medicine</i> , 2023, 11, 25-25.	0.7	6
643	Factors Predicting Worse Outcomes in an Asian Cohort of Patients With Bronchiectasis. <i>In Vivo</i> , 2022, 36, 2993-2998.	0.6	1
644	Cardiovascular and cerebrovascular-associated mortality in patients with preceding bronchiectasis exacerbation. <i>Therapeutic Advances in Respiratory Disease</i> , 2022, 16, 175346662211442.	1.0	1
645	The incidence of bronchiectasis in chronic obstructive pulmonary disease. <i>Open Medicine (Poland)</i> , 2022, 17, 1927-1934.	0.6	1
646	Nontuberculous mycobacteria infection and pulmonary disease in bronchiectasis. <i>ERJ Open Research</i> , 2022, 8, 00060-2022.	1.1	3
647	“Teach me how to look after myself”: What people with bronchiectasis want from education in a pulmonary rehabilitation setting. <i>Clinical Respiratory Journal</i> , 0, , .	0.6	3
648	Motile ciliary disorders of the nasal epithelium in adults with bronchiectasis. <i>Chest</i> , 2022, , .	0.4	1
649	Bronchiectasis in severe asthma is associated with eosinophilic airway inflammation and activation. , 2022, , .		2
650	Inhaled Colistimethate Sodium in the Management of Patients with Bronchiectasis Infected by <i>Pseudomonas aeruginosa</i> : A Narrative Review of Current Evidence. <i>Infection and Drug Resistance</i> , 0, Volume 15, 7271-7292.	1.1	4
651	Physiotherapy management of bronchiectasis in adults. <i>Journal of Physiotherapy</i> , 2023, 69, 7-14.	0.7	2
652	The Establishment of China Bronchiectasis Registry and Research Collaboration (BE-China): Protocol of a prospective multicenter observational study. <i>Respiratory Research</i> , 2022, 23, .	1.4	3
653	Genetic and Serum Screening for Alpha-1-Antitrypsin Deficiency in Adult Patients with Cystic Fibrosis: A Single-Center Experience. <i>Biomedicines</i> , 2022, 10, 3248.	1.4	1
654	The BATTLE study: Effects of long-term tobramycin inhalation solution (TIS) once daily on exacerbation rate in patients with non-cystic fibrosis bronchiectasis. Study protocol of a double blind, randomized, placebo-controlled trial: study protocol. <i>Contemporary Clinical Trials Communications</i> . 2022. 30. 101045.	0.5	2
655	Reliability and Validity of Computerized Adventitious Respiratory Sounds in People with Bronchiectasis. <i>Journal of Clinical Medicine</i> , 2022, 11, 7509.	1.0	0
656	Long-Term Domiciliary High-Flow Nasal Therapy in Patients with Bronchiectasis: A Preliminary Retrospective Observational Case-Control Study. <i>Journal of Clinical Medicine</i> , 2022, 11, 7323.	1.0	7

#	ARTICLE	IF	CITATIONS
657	Effects of long-term tobramycin inhalation solution (TIS) once daily on exacerbation rate in patients with non-cystic fibrosis bronchiectasis. <i>Respiratory Research</i> , 2022, 23, .	1.4	4
658	Bacteriophage: A new therapeutic player to combat neutrophilic inflammation in chronic airway diseases. <i>Frontiers in Medicine</i> , 0, 9, .	1.2	0
659	Impacts of Asthma in Patients With Bronchiectasis: Findings From the KMBARC Registry. <i>Allergy, Asthma and Immunology Research</i> , 2023, 15, 83.	1.1	0
660	Bronchiectasis in low- and middle-income countries: the importance of the wider view. <i>European Respiratory Journal</i> , 2023, 61, 2201977.	3.1	1
662	Insights into Personalised Medicine in Bronchiectasis. <i>Journal of Personalized Medicine</i> , 2023, 13, 133.	1.1	1
664	The impact of depression and anxiety on the risk of exacerbation in adults with bronchiectasis: a prospective cohort study. <i>European Respiratory Journal</i> , 2023, 61, 2201695.	3.1	2
665	Clinical Study of Modified Yupingfeng Powder in the Treatment of Bronchiectasis Based on the Theory of Spleen Invigorating and Lung Benefiting. <i>Traditional Chinese Medicine</i> , 2023, 12, 311-316.	0.1	0
666	Risk Factors for Influenza-Induced Exacerbations and Mortality in Non-Cystic Fibrosis Bronchiectasis. <i>Viruses</i> , 2023, 15, 537.	1.5	3
667	Active cycle of breathing technique versus oscillating PEP therapy versus walking with huffing during an acute exacerbation of bronchiectasis: a randomised, controlled trial protocol. <i>BMC Pulmonary Medicine</i> , 2023, 23, .	0.8	2
669	Global research status and trends of bronchiectasis in children from 2003 to 2022: A 20-year bibliometric analysis. <i>Frontiers in Pediatrics</i> , 0, 11, .	0.9	1
670	Risk factors and prognostic value of osteoporosis in hospitalized patients with bronchiectasis. <i>BMC Pulmonary Medicine</i> , 2023, 23, .	0.8	2
671	The Lung Transplant Candidate, Indications, Timing, and Selection Criteria. <i>Clinics in Chest Medicine</i> , 2023, 44, 15-33.	0.8	0
672	Association Between Viscoelastic Characteristics and Sputum Colour in Patients With Bronchiectasis. <i>Archivos De Bronconeumologia</i> , 2023, 59, 406-408.	0.4	1
674	Low Salivary Secretory Leukocyte Protease Inhibitor Levels Are Related to Airway Pseudomonas aeruginosa Infection in Bronchiectasis. <i>Chest</i> , 2023, , .	0.4	0
675	Clinical relevance of bronchiectasis in patients with community-acquired pneumonia. <i>American Journal of the Medical Sciences</i> , 2023, 365, 502-509.	0.4	1
676	Towards development of evidence to inform recommendations for the evaluation and management of bronchiectasis. <i>Respiratory Medicine</i> , 2023, 211, 107217.	1.3	2
677	Features of osteoporosis in male patients with bronchiectasis, a cross-sectional study. <i>Journal of Thoracic Disease</i> , 2023, 15, 1177-1185.	0.6	0
678	Diffuse Bronchiectasis of Genetic or Idiopathic Origin. , 2023, , 441-462.		0

#	ARTICLE	IF	CITATIONS
679	The role of precision medicine in bronchiectasis: emerging data and clinical implications. Expert Review of Respiratory Medicine, 2023, 17, 279-293.	1.0	0
680	The U-Shaped Relationship Between Eosinophil Count and Bronchiectasis Severity. Chest, 2023, 164, 606-613.	0.4	11
687	Bronchiectasis: from orphan disease to precision medicine. , 2023, , 150-164.		0
728	Bronchiectasis: An Evidence-Based Approach to Diagnosis. Current Pulmonology Reports, 2024, 13, 47-56.	0.5	0
729	Non-CF Bronchiectasis. , 2024, , 93-113.		0